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ABSTRACT
The Effect of Dietary Creatine Supplementation on Compensatory Muscle 
Hypertrophy and Performance Characteristics of Specific Fiber Types
by
Robert Earl Young
Dr. Lawrence A_ Golding, Examination Committee Chair 
Distinguished Professor of Kinesiology 
University o f Nevada, Las Vegas
An animal model was used to determine the effect of dietary creatine 
supplementation on compensatory muscular hypertrophy and electrically stimulated 
performance o f those muscles. Thirty-six rats were divided evenly into six groups. Two 
groups were surgical controls, two groups had the tibialis anterior ablated, to hypertrophy 
the extensor digitorum longus (EDL), and two groups the gastrocnemius and the plantaris 
ablated, to hypertrophy the soleus. One of each of these groups had their diet 
supplemented with creatine monohydrate. The size of the EDL and soleus were 
measured following surgical removal o f  the synergistic muscle and a 5-week 
supplementation period. Peak force, total tension over two 30 second intervals and time 
to one-half peak force were measured from the electrically stimulated muscle. Results 
indicated no difference in muscle size, peak force or tension due to the supplement. Time 
to one-half fatigue was increased in hypertrophied, non-supplemented soleus muscle.
in
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CHAPTER 1
INTRODUCTION 
Creatine (Cr) is a naturally occurring conqx)und found within muscle cells 
(Figure 1 ). It is obtained in the diet from meat and fish, or it can by synthesized 
endogenously in the liver, pancreas and kidneys from methionine, glycine, and arginine. 
Cr is phosphorylated, via creatine kinase, to Phosphocreatine (PCr). PCr is a high-energy 
compound that supports the re-synthesis o f ATP during the initial s t^ e s  o f  intense 
muscular activity (Greenhaff, 1995; Hirvonen, Rehunen, Rusko & Harkonen, 1987; 
Hukman, Bergstrom & Anderson, 1967). Studies have shown that dietary supplements 
o f  Cr will result in increased Cr and PCr in the skeletal muscle. A typical supplement 
protocol o f  5g Cr 4 times a day, for 5 to 10 days, will increase total Cr and PCr (Balsom, 
Soderlund & Ekblom, 1994; Balsom, Soderlund, Sjodin & Ekblom, 1995; Green, 
Simpson, Littlewood, MacDonald & Greenhaff 1996; Greenhaff Bodin, Soderlund & 
Hukman, 1994; Harris, Soderlund & Hukman, 1992; Hukman, Soderlund, Timmons, 
Cederblad & Greenhaff 1996; Kreider, 1995). PCr stores are normally depleted within 
the first 20-seconds o f  high intensity exercise (Hukman, Greenhaff Ren & Soderlund, 
1990). Within one minute o f  exercise termination PCr levels are restored to 50% o f  pre­
exercise values (Tesch, Thorsson & Fujftsuka, 1989). Conçlete restoration o f  PCr 
occurs about 20-minutes post exercise, however after 6-minutes PCr stores have returned
to 80 to 90% of resting levels (Harris, Edwards, Hukman, Nordesjo, Nylind & Sahlin,
1
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1976). For this reason Cr supplementation is thought to have an ergogenic effect, that 
will enhance athletic performance in activities that consist of short duration, high 
intensity muscular activity (le. sprinting, cycling, swimming, as well as, weight lifting). 
Cr supplementation may also affect those activities that feature repeated bouts o f intense 
activity (Le. hockey, soccer, basketball and tennis). Recent studies have yielded mixed 
results regarding the effect o f Cr supplementation on athletic performance (Balsom, 
Harridge, Soderlund, Sjodin & Ekblom, 1993; Rossker, Cannell & Jakeman, 1996; 
Mujika & Padilla, 1997; MujOca, Chatard, Lacoste, Barale & Geyssant, 1996; Kreider, 
Ferreira, Wilson, Grindstaff, Plisk, Reinardy, Cantler & Almada, 1998). The vast 
majority o f studies have focused on humans and their performance in various running and 
cycling protocols, but the total amount o f research involving Cr supplementation is still 
too small and the results too varied to draw strong conclusions. A few more recent 
studies have focused on Cr supplementation and weight training. Cr supplementation may 
have an ergogenic effect on muscle hypertrophy (Kreider, 1995; Earnest, Snell, 
Rodriguez, Almada & Mitchell, 1995; Kreider, et al, 1998), but the results are still 
inconclusive. The purpose o f this study is to investigate the effects of Cr 
supplementation on muscle hypertrophy and the performance of those muscles, using an 
animal model The use o f an animal model will eliminate many problems inherent in 
human studies, namely placebo effect and the variability o f athletic performance. Animal 
models have long been used in physiological studies to provide greater control o f the 
variables involved with the studies.
In rats, muscle hypertrophy has been produced through surgical removal, or 
ablation, o f a synergistic muscle, with more success than many other methods including 
tenotomy, passive muscle stretch, and exercise induced enlargement (Timson, 1990).
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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Ablation o f  the gastrocnemius and plantaris results in compensatory hypertrophy o f the 
soleus, by 60 to 90% over control muscle size (Young, Kandarian & Kurowski, 1992; 
Kandarian, Young & Gomez, 1992; Kandarian & White, 1990). Ablation o f  the tibialis 
anterior (TA) results in hypertrophy o f the extensor digitorum longus (EDL), by 
approximately 60% over control muscles (Young, Kandarian & Kurowski, 1992). In this 
study the soleus and EDL were chosen to represent two different types o f  muscle fiber. 
The soleus is predominantly slow twitch, while the EDL is predominantly fast twitch.
I f  Cr supplementation has an ergogenic affect, the animals that receive Cr should 
exhibit a greater degree o f hypertrophy. Those hypertrophied muscles should produce a 
higher peak force, higher total tension and have an increased time to fotigue when 
exercised (electrically stimulated) maximally  to exhaustion.
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
CHAPTER 2
REVIEW OF LITERATURE
Creatine is synthesized by the liver, pancreas and kidneys from the amino acids
arginine, glycine and methionine (Figure 2) (Balsom, Soderlund & Ekblom, 1994;
Bessman & Carpenter, 1985). Cr is also obtained through the dietary intake o f  meat and
fish (Balsom et al 1994; Delanghe, De Slypere, Buyzere, Robbrecht, Weime &
Vermeulen, 1989). The vast majority, 95%, of Cr is transported, via the blood stream
(Jacobson, Christensen, Mogensen, Andresen & Heilskov, 1979), from sites o f
production to the skeletal muscle; the rest is distributed between the brain, testes and
cardiac tissue (Balsom et al, 1994). Cr will react, nonenzymatically, to form creatinine
(Bessman & Capenter, 1985), a  waste product that is processed by the kidneys and
excreted (Delanghe et al, 1989). The hydrolysis o f Cr to creatinine takes place at a
constant rate, approximately 2g/day in the human body (Balsom et al, 1994).
PCr is involved in muscular energetics as a high-energy phosphate donor. PCr
has a large free energy o f  hydrolysis, about 10 Kcal/mol (Meyerhof & Lohman, 1932).
Lipmann and Meyerhoff (1930) demonstrated that creatine was released during muscular
contraction, and concluded that the hydrolysis of PCr was coupled to muscular
contraction. While adenosine triphosphate (ATP) was discovered around the same time
(Fiske & Subbarow, 1929), it was not until the early 1960’s that ATP was shown to be
the direct source o f  energy for muscular contraction (Cain & Davies, 1962). ATP can be
4
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formed in one o f  three different ways: I. Oxidative Phosphorylation in the mitochondria. 
2. Transphosphorylation o f  PCr, or 3. Transphosphorylation o f  adenosine diphosphate 
(ADP) (Hukman, Bergstrom & Anderson, 1967). In 1978 Bessman proposed the 
“Creatine Phosphate ShuttIe”(CPS). The CPS is diagramed in Figure 3. PCr is 
synthesized by the mkochondria. It then diffuses to the myofibrils where the enzyme 
creatine kinase is bound. As ADP is generated during contraction, creatine kinase 
catalyzes the formation o f  ATP through the following reaction: PCr + ADP o  Cr + ATP. 
The free Cr then diffuses back to the mkochondria, where k can be rephosphorylated. 
(Bessman & Carpenter, 1985) The CPS is also supported by the observation that adenine 
nucleotides are compartmentalized to the mkochondria or the peripheral ATPases (i.e. 
myofibrils) (Perry, 1954; Mommaerts, 1954; Hill, 1960).
While PCr is not directly responsible for muscular contraction, k is a significant 
determinant for muscular activity. After short duration, high intensity exercise to fetigue, 
ATP levels remain relatively normal, while PCr levels are nearly depleted (Hukman, 
Bergstrom & Anderson, 1967; Fkts, 1994; Westerblad, Lee, Lannergren & Allen, 1991; 
Sahlin, Tonkongi & Sodelund, 1998). An enlargement of the phosphocreatine pool 
should enhance the cells abilky to regenerate ATP during periods o f extremely high 
energy requirements.
Cr has been shown to stimulate myofibril protein synthesis (Sipila, R^x>la,
Simell, 1981). This finding was limked to the treatment o f choroid retina atrophy, and 
has yet to be duplicated. One hypothesized explanation of this finding may be that Cr 
stimulates GTP production, which is required to inkiate protein synthesis. Akemately k 
has been hypothesized that Cr may induce cellular swelling through ks osmotic activity. 
This swelling or vohimizing may influence hormones and amino acids that regulate
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metabolic control and in turn modulate anabolic activity or protein synthesis (Plisk & 
Kreider, 1999). Muscles depleted o f Cr atrophy (Fitch & Chevli, 1980; Fitch, Chevli, 
Petrofeky & Kopp, 1978; Fitch, Jellinek, Fkts, Baldwin & HoUoszy, 1975). Possible 
mechanisms o f  atrophy include the loss o f protein bound Cr, reduced Cr-cofector effect 
on myosin synthesis, or in^jaired energy supply (Plisk & Kreider, 1999). If  normal 
resting Cr levels are low, increasing Cr may resuk in an augmented response in protein 
synthesis.
Dietary supplementation o f  Cr monohydrate has been shown to increase muscle 
total Cr by approximately 20% over a one-week period (Harris, Soderlund & Hukman, 
1992; Hultman, et al, 1996), however inkial levels o f muscle Cr are a foctor in the 
amount o f  increase observed (Casey, Constantin-Teodosiu, Howell, Hukman & 
Greenhaff 1996). Individuals wkh lower resting concentrations will demonstrate a 
greater increase then individuals wkh higher resting levels (Delanghe, et al, 1989). 
Normal resting total Cr concentrations in non-supplemented humans are approximately 
125 mmol/Kg o f  dry muscle (Harris, Hukman & Nordjesjo, 1974). It does appear, in 
humans, however that an upper limk o f  Cr concentration o f  150 to 160 mmol/ Kg can be 
reached wkh prolonged supplementation (Mujika & Padilla, 1997). Supplementation, 
however, is not without adverse side effects. Anecdotal claims o f minor gastrointestinal 
distress, nausea and muscle cramping have been reported, although the number o f cases 
is very small compared to the total number of participants in all studies. Renal function, 
as measured by glomerular ffkratkm rate and protein and albumen excretion rates, does 
not appear to be affected (Poortmans, Auquier & Renaut, 1997). Endogenous creatine 
synthesis is reduced during periods o f supplementation, but returns to normal when 
supplementation is stopped (Hukman, et al, 1996).
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Dietary supplementation o f Cr has been affected by caffeine and carbohydrate 
consumption, although the mechanism o f Cr uptake, into the cell, has yet to be 
determined. Caffeine consun^tion in conjunction with Cr supplementation negates the 
ergogenic effect o f  Cr (Vandenberghe, Gillis, Van Leemputt, Van Hecke, Vanstapel & 
Hespel, 1996). Muscle Cr and PCr was increased by supplementation o f Cr in 
conjunction with caffeine, but Vandenberghe, et al found that muscular performance is 
not enhanced. This may account for some o f  the negative or non-significant results seen 
in some performance studies. Ingestion o f  carbohydrates alor^ with Cr increases the 
retention o f Cr within the cell (Green, et al, 1996). Green, et al, found that ingesting 5 g 
o f  Cr with 93 g o f a simple carbohydrate solution augmented creatine retention, when 
conçared to ingesting 5 g Cr with a sugar fiee solution. Cr retention was not further 
enhanced by exercise prior to ingestion o f the Cr and carbohydrate solution.
Cr supplementation has been shown to enhance performance in cycling (Casey, et 
al, 1996; Jacobs, Bleue & Goodman, 1997; Birch, Noble, Greenhaff 1994; Balsom, et af 
1995), swimming (Grindstaff Kreider, Bishop, Wilson, Wood, Alexander & Almada, 
1997), running (Harris, Vim, Greenhaff & Hultman, 1993) and kayaking (McNaughton, 
Dalton & Tarr, 1999). Cr has also been shown to increase measures o f strength and 
anaerobic power (Kreider, et al, 1998; Kreider, 1995; Earnest, et a f 1995; Greenhaff 
Casey, Short, Harris, Soderlund & Hukman, 1993). These studies have utilized maximal 
exercise (100 to 125 % V 02 max) over very short periods o f  time (less than 3 minutes).
Several studies have foiled to show any difference between Cr and Placebo 
supplemented groups in cycling (Bamett, Hinds & Jenkins, 1996; Cooke, Grandjean & 
Barnes, 1995; Febbraio, Flangan, Snow, Zhao & Carey, 1995; Cooke & Bames, 1997), 
Swimming (Mujika, et al, 1996; Burke, Pyne & Telford, 1996), running (Balsom, et af
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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1993; Redondo, Dowling, Graham, Alamada & Williams, 1996; Terriliion, Kolkhorst, 
Dolgener & Joslyn, 1997; Stroud, Holliman, Bell, Green, MacDonald & Greenhaff,
1994), rowing (Rossiter, Cannell & Jakeman, 1996) and isometric exercise (Greenhaff, et 
a l  1994; Greenhaff, Bodin, Harris, Hukman, Jones, McIntyre, Soderlund & Turner,
1993).
Jacobs, Bleue and Goodman, in 1997, showed that a 5 day Cr supplementation 
program increased the maximum accumulated oxygen deficit (MAOD) and time to 
exhaustion during cycling. Participants peddled at 125% of their V02 max, following a 
3-minute warm up, until exhaustion, before and after the 5-day period of 
supplementation. MAOD and time o f  exhaustion were increased in the Cr group as 
compared to the placebo group. While no change was seen in the placebo group, a 
relative increase in MAOD o f  about 10% (0.4 L) and a 9% (about 10 s) increase in time 
to exhaustion was seen in the Cr group. The lingering effects o f Cr supplementation were 
measured as participants repeated the test 7 days later, following the removal o f  the Cr 
supplement fi'om the diet. MAOD and time to exhaustion remained elevated in the Cr 
group following 7 days wkhout supplementation.
Harris, Vim, Greenhaff and Hukman in 1993, demonstrated that a 5-day Cr 
supplementation program decreased times in repeated bouts o f running. Trained middle 
distance runners were divided into two groups, placebo and Cr. Participants ran 4X300 
meter, and 4X1000 meter runs on separate days, wkh 4 and 3-minute rest intervals, 
respectively, before and after 5 days o f  Cr or placebo supplementation. Total time for the 
4 trials as each distance was decreased in the Cr group, as was the time for the last trial o f  
each distance. Best 300 and lOOO-meter times were also significantly decreased in the Cr 
group.
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Grindstaff Kreider, Bishop, Wilson, Wood, Alexander and Almada in 1997 found 
that 9 days o f  Cr supplementation decreased times in 3 100-meter swim sprints. 
Participants performed 3 100-meter sprints with I-minute rest in between, before and 
after 9 days o f  Cr or placebo supplementation. Following supplementation, times for the 
first two o f  the three trials were significantly foster in the Cr group. When compared to 
pre-supplement trials the Cr group swam only slightly foster in the first two trials. The 
difference between the placebo and Cr groiqjs was mainly due to the slower times o f the 
placebo group. No significant differences were detected in the third trial.
Kreider, Ferreira, Wilson, Grindstaff Plisk, Reinardy, Cantler and Almada in 
1998 determined the effects o f  a 28-day Cr supplementation program on body 
composition, strength and sprint performance. Results indicated that Cr supplementation 
had no effect on the percentage o f  total body water, while total body weight increased in 
the Cr group. The increase was in part due to an increase in fat/bone free mass.
Measures o f strength, including bench press lifting volume and the sum of bench press, 
squat and power lifting volumes, increased in the Cr group. Bench press volume 
increased by an average o f225 kg while a minimal decrease, -5 kg, was seen in the 
placebo group. The sum of the three lifting volumes increased 1,558 kg in the Cr group 
compared to a 1,105 kg increase in the placebo group. No difference was seen in the 
volumes o f  the squat or power lift between the two groups. Total work for the first 5 of 
12 6-sec cycling sprints was increased in the Cr groiç, resulting in a significant 
difference in the total work for the 12 sprints.
Birch, Noble and Greenhaff in 1994, studied the effects o f Cr supplementation on 
maximal isokinetic cycling. Participants were tested before and after a 5-day, Cr or 
placebo, supplementation regime. Testing consisted o f 3 30-sec bouts of maximal
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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cycling, separated by 4-tnin o f  passive recovery. Peak power output (PPO) and mean 
power output (MPO) were measured during each bout. Peak power was significantly 
increased by Cr supplementation in bout 1 and MPO was significantly increased in bouts 
1 and 2. There was no difference in bout 3.
Balsom, Soderlund, Sjodin and Ekblom, in 1995, determined the effect o f  Cr 
supplementation on high-intensity cycling. Participants were tested before and after a 6- 
day Cr supplementation intervention. The exercise protocol consisted o f  5 6-sec 
ergometric cycling sprints with 30-sec o f recovery after each sprint, followed by 1 10-sec 
sprint, 40-sec after the final 6-sec sprint. The 10-sec period was used to evaluate the 
participant’s ability to maintain power output. Results indicated that target speed was 
better maintained following Cr supplementation. Target speed was maintained during 
each o f the 6-sec periods. The total work done in the 6-sec periods was the same after 
supplementation as it was before. Muscle biopsies indicated that total Cr was increased 
by supplementation. PCr concentrations were higher in post exercise measurements 
following supplementation. Increased performance in the 10-sec bout is attributed to this 
higher post-exercise PCr concentration. The increase in total Cr was accompanied by 
1.1-kg increase in body weight over the 6 days o f  supplementation.
Casey, Constantin-Teodosiu, Hultman and Greenhaff in 1996, reported the 
effects of Cr supplementation on maximal ergometric cycling. Participants performed 2 
30-sec bouts o f maximal cycling before and after 5-days of Cr ingestion. Total work 
production during post-supplement bouts 1 and 2 increased by about 4%, as did peak 
work output during each bout. This increase was positively correlated with the increase 
in total muscle Cr, measured by muscle biopsy. Any change in body weight was not 
mentioned.
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Greenhaff Casey, Short, Harris, Soderlund and Hultman, in 1993, investigated 
the effects o f  Cr supplementation on maximal isokinetic knee extensions. Muscle torque 
production was measured during each contraction in a series o f 5 bouts o f 30 unilateral 
knee extensions, with 1-min rest between bouts. Participants were tested before and after 
5-days o f  Cr or placebo supplementation. No difference was seen in the performance o f 
the placebo group. Muscular torque in the Cr group was increased in the last 10 
contractions o f bout 1, aU contractions in bout 2, 3 and 4, and the middle 10 contractions 
o f  bout 5, when conq)ared to corresponding values in pre-supplement trial.
Earnest, Snell, Rodriguez, Almada and Mitchell, in 1995, demonstrated the effect 
o f  Cr supplementation on measures o f  anaerobic power, muscular strength and body 
composition. Anaerobic power was measured by 3 30-sec Windgate bike tests.
Muscular strength was measured by a one repetition maximum (1 RM) bench press, and 
total bench press lifting volume calculated from repetitions o f 70% 1 RM until fatigue. 
Body conqx)sition was measured by hydrostatic weighing. A group of strer%th trained 
athletes performed a series of workouts before and after 14 days (windgate tests) and 28 
days (weight lifting and body composition) o f  Cr or placebo supplementation. Results 
indicated an increase in total anaerobic work for the windgate tests for the Cr group, 
while no change was seen in the placebo group. The increase was 13, 18 and 18% for 
bouts 1, 2 and 3 respectively. Bench-press max was higher in the Cr group, but the 
increase was negated when corrected for body weight. The Cr group demonstrated a 
significant increase in body weight. Total lifting volume was also significantly increased 
in the Cr group, whether ejqjressed in absolute or relative terms. The Cr group performed 
an average o f  26% more repetitions than the placebo group. The significant increase in
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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body weight, o f  the Cr group, was accompanied by a  non-significant increase in fat free 
mass. No changes in body composition were noted within the placebo group.
Kreider, in 1995, illustrated the effects o f Cr supplementation on strength training 
and weight gain. Participants in the 28-day study were randomly assigned to one o f three 
groups, pure carbohydrate; a mixture o f carbohydrate, protein, fet and creatine; and a 
mixture of carbohydrate, protein, fot, chromium and boron. The Cr group gained an 
average o f 2 kg while the other groups only gained about 0.6 kg. No significant 
differences were seen in total body water, so increased body weight was attributed to an 
increase in lean body mass. Participants also under went strength testing. Results 
indicate that Cr has a slight affect on peak power, peak force and total work during 
isokinetic multijoint exercises, after 7 days o f supplementation. Further supplementation 
does not appear to have an affect on performance.
McNaughton, Dalton and Tarr, in 1999, illustrated the effects o f 5 days o f  Cr 
supplementation on kayak ergometry. Participants performed 3 maximal kayak 
ergometer tests o f 90, 150 and 300 sec duration, before and after 5 days o f  Cr or placebo 
supplementation. Participants were then re-tested following a 4-week “wash out” period 
before and after 5 days of cross over supplementation. Results showed that the group re­
tested after Cr supplementation performed significantly greater in all trials. Work 
completed was approximately 3 kJ more in all trials (90,150 and 300 s) following Cr 
supplementation. Body mass was significantly greater in the Cr group.
Ôôpik, Paasuke, Timpmann, Medijainen, Ereline and Smirnova, in 1999, reported 
the effects o f a 5-day Cr supplementation regime on isokinetic power when coupled with 
r ^ id  weight loss. Peak torque and work at peak torque o f the knee extensors were 
determined in each participant before and after Cr or placebo supplementation.
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Intermittent high intensity working capacity o f the knee extensors was also measured by 
a series o f sub-maximal isokinetic knee extensions, at specific angular velocities, for 45s 
at a rate o f 30 contractions per minute, followed by 15 seconds o f maximal effort. This 
series was repeated 3 times for a total testing period o f 3 minutes. Results indicated that 
Cr supplementation maintained peak torque and work at peak torque when conq)ared to 
the placebo group. Cr supplementation had no effect on maximal work or on the rate o f 
fatigue during maximal woric. Results also indicated that Cr supplementation had an 
adverse effect on sub-maximal work. Total sub-maximal work in the Cr group was 
significantly lower in the second and third minute o f  the post supplement test period 
when conqiared to pre-supplement values.
Smith, Stephens, Hall, Jackson and Earnest, in 1999, investigated the effect o f Cr 
supplementation on work aixi time to fetigue in exhaustive constant power exercises at 
different intensities. Participants preformed cycle ergometer tests to determine the work 
X time relationship, then 4 bouts o f exercise at an intensity selected to elicit fotigue in 90 
to 600 s, before and after 5 days of Cr or placebo supplementation Results indicated an 
improved time to fetigue in the Cr group for all but the lowest intensity.
Terriliion, Kolkhorst, Dolgener and Joslyn in 1997 investigated the effect o f a 5- 
day Cr supplementation period on 2 maximal 700-meter runs. No significant differences 
were seen in the performance between the Cr and placebo groups. Placebo group 
participants ran 110.2±3.5 and 110.4db3.0 sec in the pre-supplement trial and 108.5±2.9 
and 108.0±1.7 in the post-supplement trials. Cr group times were 109.9±3.2 and 
110.4±3.6 for pre-supplement trials and 109.7+3.3 and 107.8+2.2 sec in the post­
supplement trials. Differences between the placebo and Cr group were not significant. It
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was also noted that no differences in weight gain were seen. It was concluded that 
maximal bouts o f exercise 90 to 120 sec in duration might be too long to see the effects 
o f  Cr suppIementatioiL
Redondo, Dowling, Graham, Almada and Williams, in 1996, tested the effect o f 
Cr supplementation on maximal running velocity. Participants performed three 60-meter 
sprints prior to and following a 7-day Cr or placebo supplementation protocol. Maximal 
running velocities were calculated from video taped performances of the sprints. Results 
indicated that Cr supplementation did not influence the running velocities o f  the two 
groups. Also no difference in weight gain was reported between the two groups.
Bamett, Hinds and Jenkins, in 1996, reported the effects of Cr supplementation on 
repeated 10-sec sprint cycle performance. Participants were pre-tested for Max V 0 2  and 
7 maximal 10-sec cycle ergometer sprints. Each sprint was separated by 30 sec o f  
passive rest except for sprints 5 and 6, which were separated by 5 minutes. Peak power 
output (PPO), mean power output (MPO), end power output (EPO) and percent power 
decline were measured for each subject. Participants were cohort matched following the 
pre-test. Cr or placebo was supplemented in the diet for 4 days. Following 
supplementation Max V 02 and sprint cycle performance were again measured. Results 
indicated that Max V02 and all aspects o f  sprint cycle performance were unchanged after 
4 days o f supplementation. Body weight also remained unchanged after 
supplementation.
Mujika, Chatard, Lacoste, Barale and Geyssant, in 1996, reported the effects o f  Cr 
supplementation on sprint swim performance. A  group o f  highly trained swimmers was 
pre-tested for time and blood ammonia and lactate after 25, 50 and 100 meter sprints in 
their best stroke. The group was then divided into 2 groups, Cr and placebo. Participants
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were re-tested following 5 days o f  Cr or placebo supplementation. Results foiled to show 
any difference in performance times at each distance, however post exercise blood 
ammonia levels were lower in the Cr group following the 50 and 100 meter sprints.
Blood ammonia levels were only decreased in the placebo group following the 50-meter 
sprint. No changes in lactate were seen. A significant increase in body weight (1kg) was 
seen in the Cr group as compared to the placebo group.
Greenhaf^ Bodin, Soderhind and Huhman, in 1994, investigated the affect o f  Cr 
on phosphocreatine resynthesis and isometric contractions. Muscle biopsies were 
obtained from participants at 0, 20, 60 and 120-sec following electrically evoked 
isometric knee extensions, before and after 5 days o f Cr supplementation. Results 
indicate that Cr supplementation had a positive affect on PCr resynthesis in 5 o f the 8 
participants. Supplementation increased recovery by about 35% after 2 minutes, 
compared to pre-supplement values in those individuals. This response was coupled with 
a 25% increase in total muscle Cr. The other 3 participants foiled to produce signiGcant 
increases in total Cr, and showed no change in PCr resynthesis.
Vandenberghe, Van Heck, Van Leemputte, Vanstapel and Hespel, in 1999, also 
studied the affects o f Cr supplementation on PCr resynthesis. Participants under went ^*P 
NMR spectroscopy o f  the m. gastrocnemius, before during and after isometric plantar 
flexion, before and after 2 and 5 days o f Cr or placebo supplementation. Resting PCr 
concentrations were increased by 11% after 2 days and 16% after 5 days. However, PCr 
breakdown and resynthesis were not significantly different from the placebo group. 
Participants also under went a series o f isokinetic knee extensions to evaluate dynamic 
strength and fotigability. Torque production during maximal knee extensions was 
increased in the Cr group during the first o f  five bouts o f  30 extensions.
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Stroud, Holliman, Bell, Green, MacDonald and Greenhaff, in 1994, studied the 
effects o f Cr supplementation on steady state, incremental treadmill exercise and 
recovery. Participants performed treadmill running at 10 km/h at predetermined grades 
to elicit workloads between 50 and 90% o f  V 02 max, before and after 5 days o f  Cr 
supplementation. Each workload lasted 6 minutes in duration and respiratory gas 
exchange and blood lactate concentrations were measured during the last 30 s o f  each 
stage, and every 5 minutes during a 15-minute recovery. Results indicated that Cr 
supplementation had no measurable effect on respiratory gas exchange or blood lactate 
concentrations, during exercise or recovery. Oxygen consumption and respiratory 
exchange ratio were not significantly different fi’om pre to post supplement measures. A 
significant gain in body weight was seen from pre to post, with participants gaining about 
1 kg over the 5 days o f  supplementation.
Balsom, Harridge, Soderhmd, Sjodin and Ekblom, in 1993, reported the effects o f 
Cr supplementation on endurance performance. Participants performed treadmill runs o f 
12% V02 max and 6 km terrain runs before and after 6 days of Cr or placebo 
supplementation. Results indicated that Cr had no positive effect on performance in 
either the treadmill or terrain runs. The time on the post-supplement terrain run was 
significantly longer in the Cr group. This increase in time is thought to in part be due to a 
significant increase in body mass, seen in the Cr group over the 6 days of 
supplementation.
Cooke and Barnes, in 1997, reported the effects of Cr supplementation on high 
intensity exercise following a recovery period. Participants performed two maximal 
cycle ergometer sprints with one of four recovery intervals (30, 60 90 or 120 s), before 
and after a 5 day Cr or placebo supplementation. Results failed to demonstrate a
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significant effect for Cr in any case. No difference in peak power or time to fatigue of 
the first or second trial was seen fi*om pre to post supplementation. Peak power and time 
to fotigue were decreased from trial 1 to 2, but not significantly different from placebo to 
Cr.
Cooke, Grandjean and Bames, in 1995, demonstrated the effects o f Cr 
supplementation on power output and fetigue in cycle ergometry. Participants performed 
2 ,15 s consecutive maximal power tests before and after 5 days of Cr or placebo 
supplementation. No differences in peak power, time to peak power, total work and 
fatigue index were observed between Cr and placebo groups.
Febbraio, Flanagan, Snow, Zhao and Carey, in 1995, reported the effects o f  Cr 
supplementation on intermittent supramaximal exercise. Participants performed four 
cycling trials at 115 to 125 % V 02 max with one minute rest in between, followed by a 
fifth bout to fetigue, before and after 5 days o f Cr supplementation. Participants were 
also re-tested after a 28-day washout period, the last 5 days of which were supplemented 
with placebo ingestion. No difference in the duration of the fifth bout o f  cycling was 
observed, even thought total Cr was increased following the 5 days o f Cr 
supplementation.
Burke, Pyne and Telford, in 1996, investigated the effects of Cr supplementation 
on maximal sprint efforts in elite swimmers. Participants completed 25 m, 50 m and 100 
m sprints in their best stroke, with 10 minutes o f recovery between sprints, before and 
after 5 days of Cr or placebo supplementation. Participants were divided in to two groups 
and matched for sex, stroke and time. The groups were then randomly assigned to Cr or 
placebo supplementation, prior to the second tria l Results revealed no significant 
differences in sprint times between groups.
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Rossiter, Cannell and Jakeman, in 1996, reported the effects o f Cr 
supplementation on rowing performance. Participants completed a 1000 m simulated 
row before and after 5 days o f  Cr or placebo supplementation. Results revealed an 
overall decrease, about 1% or 2.3 s, in rowing time for the Cr group, however, and this 
difference was not significantly different form the placebo group.
One study has investigated the effects o f  Cr supplementation on rat skeletal 
muscle. Brannon, Adams, Conniff, and Baldwin, in 1997, reported the effect o f  Cr 
loading on running performance in rats. Running performance was assessed by duration 
and interval performance on treadmill runs, following 10 days of either a normal diet or a 
Cr supplemented diet. The duration test consisted o f running at 60 m per min, on a 15% 
grade. This was designed to fotigue the animals in less than 2 minutes. After a two-day 
recovery period the rats then performed an interval test wdiich involved 30 s o f running 
with 30 s recovery periods. Running was performed at 13 m per min also at 15% grade. 
The test was stopped wdien the rat could no longer complete a 30 s run. Following this 
initial performance testing the rats were further divided in to groups to assess the effect o f 
prolonged supplementation and training. After a 4 week training period the rats were 
again tested for duration and interval results. Results indicated that Cr supplementation 
enhanced running performance after 10 days, but no further gains were seen after 28 days 
o f  Cr supplementation. Cr animals ran significantly longer in the duration test after 10 
days, but no difference in interval performance was seen. Following 4 weeks o f  training 
the CrAraining group performed significantly better in duration and interval performance 
than training alone and both tl% non-training  groups.
Many studies have been conducted to determine the ergogenic effects o f  Cr, but 
results are still inconclusive. Only one o f these studies has used an animal model, the rest
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have focused directly on humans. The studies that have shown a positive effect generally 
utilize untrained or moderately trained participants. Protocols in these studies usually 
consist o f highly intense activity, 100 to 125% V 02 max, in short duration, less than 3- 
minutes; or repeated bouts o f  high intensity exercise, with moderate recovery periods, 1 
to 5-minutes. Studies that have failed to show any effect o f Cr supplementation usually 
involve well-trained individuals, aerobic activities, very short or very long recovery 
periods, or have used tea or coffee to administer the Cr supplement.
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CHAPTERS 
METHODS AND PROCEDURE 
Design
The study was a 2 (Supplement) X 2 (Muscle Fiber Type) X 2 (Surgical 
Treatment) X 2 (Time) mixed design. The independent variable (TV) o f supplement, 
muscle fiber type and surgical treatment were between groups, and the IV time was 
within. The IV o f  Supplement had 2 levels, control and Cr. The IV o f Muscle Fiber 
Type had 2 levels, type I (soleus) and type II (EDL). The FV o f Surgical Treatment had 2 
levels, control and ablation. The FV o f Time had 2 levels, initial period o f  stimulation 
and recovery period o f stimulation. The dependent variables o f  interest were size o f the 
muscle, peak force produced, total tension produced and time to one half peak force.
Animals
Male Sprague-Dawley rats (n=36,183 ± 1.64 g) were randomly divided into 6
groups (m=6). Rats were housed individually and provided with food (Lab Chow) and
water ad libitum. Cr Monohydrate (Sigma, St Louis, MO) was administered to one half
o f all rats by way o f  JellO cubes, at a dose of300-mg/Kg-body weight per day. The dose
is equivalent to 20-g creatine per day for a 70 kg human. Groups 1 and 2 were surgical
controls. Group 2 received Cr Monohydrate. Groups 3 and 4 underwent tibialis anterior
20
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(TA) ablation, Group 4 received Cr Monohydrate. Groups 5 and 6 underwent 
gastrocnemius and plantaris ablation, Group 6 received Cr Monohydrate.
Ablation Procedure
Rats were anesthetized with Pentobarbital Sodium (5mg/100g body weight, ip). 
Bilateral ablations were performed. The lateral aspect o f each hindlimb was shaved and a 
longitudinal incision was made through the skin and foscia, along the lateral aspect of the 
Tibia. To ablate the gastrocnemius and plantaris, the lateral and medial heads o f the 
muscle were isolated with careful blunt dissection. The distal 1/2 o f the gastrocnemius 
and the plantaris were removed with care not to disturb the vasculature and nerves 
associated with the soleus. To ablate the TA, the distal tendon was cut and the muscle 
was removed in to-to. The fascia and skin were then sutured, distal to proximal, with 5-0 
sük. Rats were monitored during recovery for signs o f  pain, distress or discomfort. Any 
observed pain was alleviated by Butorphanol (0.1 - 0.5 mg/Kg body weight). (Kandarian 
& White, 1990; Young, Kandarian & Kurowski, 1992)
Urinary Analysis
Four weeks following the ablation surgery, 12 rats (6 Creatine and 6 controls) 
were randomly selected and placed in metabolic cages for 24 hours. Urine was collected 
and analyzed for Creatinine using a standard colorimetric assay (Hawk Practical 
Physiological Chemistry). Total Creatinine output was compared using an independent t- 
test, the accepted level o f  significance was 0.05.
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Electrical Stimulation Procedure 
Four to six weeks after the ablation surgery rats were again anesthetized with 
pentobarbital sodium (5mg/100g body weight). The sciatic nerve was ejqwsed in the 
region o f the thigh, before the separation of the tibial and common peroneal branches, but 
not cut. A dastre electrode was placed around the nerve, proximal to the bifurcation. The 
limb was fixed at the knee and ankle by steel pins inserted under the tibio-patellar 
ligament and the achilles tendon, respectively. The muscle was tied, via the distal 
tendon, to a force transducer (Narco Systems). The muscle was made to contract by 
stimulating the sciatic nerve electrically for 3 minutes, allowed to rest for 1 minute and 
stimulated again for 2 minutes, with 500ms trains o f supramaximal voltage (70V) at a 
rate of 1 train/sec (Grass Scientific Instruments). Pulses were delivered at 100 Hz, with 
each pulse in the train having a duration o f 0.1 ms. Force o f contractions were captured 
via force transducer and feed into a computerized data acquisition system (SABLE). 
Muscles were carefully removed following stimulation, all visible connective tissue was 
removed and the muscles were weighed. In EDL hypertrophy animals the soleus was 
removed by fi-eeze clamping, and in soleus hypertrophy animals the EDL was removed 
by freeze clamping. The samples were frozen and stored at -80°C. Following the 
stimulation the rats were euthanitized by an intercardial injection o f pentobarbital 
sodium. (Young & Balon, 1997)
In ablation animals only one hindlimb was stimulated, but muscles were removed 
for wet weight from each limb. Control animals had the EDL simulated in one limb and 
the soleus stimulated in the other. Both soleus and EDL from each Umb were removed 
for wet weight.
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Data Analysis
The data for dependent variables o f  peak force, tension generated, time to one- 
half peak force and size corrected force were analyzed by 2 (Supplement) X 2 (Muscle)
X 2 (Surgical Treatment) X 2 (Time) mixed modal ANOVA with repeated measures on 
the last fector. The data for the dependent variable of muscle size, percent recovery o f 
area and percent recovery o f tension were analyzed by 2(SuppIement) X 2 (Muscle) X 2 
(Surgical Treatment) ANOVA. The accepted level of significance for all tests was 0.05. 
All values reported are mean ± standard error.
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CHAPTER 4 
RESULTS AND DISCUSSION
Animal Growth and Muscle Hypertrophy 
Animal growth rates for each group were statistically different. Analysis revealed 
that the soleus hypertrophy, Cr supplement animals (Group 6) were significantly smaller 
than all other groups at the time o f stimulation (Table 1). Although the animals were 
smaller, the size o f  the hypertrophied soleus was no different than the non-supplemented 
hypertrophy group (Table 2). Muscle hypertrophy induced by the ablation surgery was 
unaffected by the supplementatioiL The EDL hypertrophied muscles in the control 
animals were slightly smaller, but not significant, 272.8 ± 24.5 and 299.3 ±38.5 mg for 
non-supplemented and Cr supplemented respectively. No difference in the size of the 
non-surgical controls was seen either. Surgical control EDL’s were 188.5 ± 6.4 mg 
without Cr, and 177.1 ±  6.2 mg with Cr added to the diet. In the soleus hypertrophied 
muscles the control animals were slightly, but not significantly, larger than the Cr 
animals, 504.8 ± 77.1 and 419.2 ± 64.3 mg respectively. No difference was seen in the 
size o f the soleus in the surgical control groups. Surgical control soleus muscles were 
172.9 ± 7.7 mg and 176.9 ± 7.6 mg, for Cr and non-Cr animals. The main difference 
between the EDL and soleus was the nature o f the ablation surgery. The tibialis anterior
24
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was removed in to-to, while in the gastrocnemius and plantaris only the distal 50% were 
removed. Cr supplementation had no effect on the muscle’s ability to hypertrophy as 
some (Plisk and Kredier, 1999) have previously suggested.
Urine Analysis
Cr supplemented animals had about 30% higher urinary creatinine outputs than 
control animals, 1.67 ±0.15 mg and 1.29 ± 0.07 mg respectively (Figure 4). This 
difference can be attributed to the dietary supplement o f Cr. An increase in total muscle 
Cr is seen in association with an increase in urinary creatinine (Delanghe, 1989; Rossiter, 
et al, 1995; Vandenberghe, et al, 1999). Increased urinary creatinine output is also 
associated with reaching an upper limit in skeletal muscle (Balsom, Soderlund and 
Ekblom, 1994; Haff and Potteiger, 1997; Juhn, 1999; Rossiter, Cannell and Jakeman, 
1995).
Peak Force
Peak force produced by electrical stimulation was also unaffected by Cr 
supplementation (Table 3, Figures 5,6). Differences between Cr and non-Cr groups were 
not statistically significant. The hypertrophied animals produced significantly greater 
force than surgical controls (41.43 ± 3.06 g and 26.76 ± 2.67 g, respectively). Peak force 
produced by each group was also significantly greater in the initial period o f  stimulation 
compared to the second period (45.77 ± 2.58 g and 22.42 ± 2.53 g, respectively). In the 
initial stimulatory period, surgical control EDL’s were able to produce 41.1 ± 3.66 g 
without Cr and 36.01 ±  9.40 g with Cr. Hypertrophied EDL’s produced 54.18 ± 4.27 g 
without Cr and 51.16 ±  8.26 g with Cr. During the recovery or second stimulatory period
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surgical controls produced 10.81 ± 3.98 g and 6.20 ± 0.69 g, with and without Cr 
respectively. Hypertrophied EDL’s produced 31.18 ±  9.87 g with Cr and 22.67 ± 2.16 g 
without Cr in the second stimulatory period. Surgical control soleus muscles produced 
41.61 ± 3.23 g without Cr and 37.11 ± 9.13 g with Cr, in the initial period and 19.93 ± 
4.88 g and 21.23 ± 6.03 g respectively in the second stimulatory period. Hypertrophied 
soleus muscles in the initial stimulation period produced 48.58 ± 10.35 g without Cr and 
56.38 ±6.16 g with Cr. In the second period hypertrophied soleus muscles produced 
36.16 ± 10.18 g without Cr and 30.51 ± 7.68 g with Cr. Hypertrophied muscles, as 
expected, produced significantly greater force than controls, but no difference was 
observed between the Cr and non-supplemented animals.
Percent Recovery of Peak Force 
The percent recovery was also unaffected by Cr supplementation. The soleus 
recovered to a significantly greater extent than the EDL (61.5 ± 6.2% and 38.7 ± 5.6%, 
respectively). Also the hypertrophied muscles recovered to a significantly greater extent 
than the surgical controls (60.2 ± 6.7% and 40.0 ± 5.2% respectively). This result is to be 
expected given that the soleus is predominantly slow twitch, fetigue resistant, while the 
EDL is a fest twitch muscle, and less fetigue resistant than the soleus. Within the EDL 
groups, Cr appeared to have a slight although not significant effect. The two groups 
receiving Cr in their diet had slightly greater percent recoveries than the two groups 
without Cr. The non-hypertrophied Cr animals recovered 38.7 ± 13.5% of their peak 
force, while the non-hypertrophied control animals recovered only 15.4 ± 1.5%. In the 
hypertrophied animals the Cr group recovered to 57.5 ± 14.5% while the non-supplement
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group recovered to only 43.2 ± 5.6% o f  their peak power. Within the soleus group, the 
effects o f Cr were less visible. The non-hypertrophied animals recovered 45.7 ±9.1% 
without Cr and 60.3 ±  6.6 % with Cr. In the hypertrophied animals the Cr group 
recovered 54.9 ± 14.0% while the non-Cr group recovered to 85.0 ± 15.7% o f their initial 
stimulation period peak force.
Size Corrected Peak Force 
Peak force produced was corrected for the size o f  the muscle to determine if any 
intrinsic changes occurred along with hypertrophy or Cr supplementation (Table 4, 
Figures 7,8). The results indicate that the hypertrophied soleus muscles produced less 
force per 100-mg muscle than the surgical controls (8.33 ± 1.18g and 17.71 ± 2.09 g, 
respectively), but no difference was seen in the EDL’s. Results also indicated that 
surgical controls produced significantly greater force in the initial period o f  stimulation 
than hypertrophied muscles (22.24 ± 1.89 g and 14.48 ± 1.58 g, respectively). No 
difference was seen in the recovery period o f  stimulation. In the initial period of 
stimulation the surgical control EDL’s produced 22.04 ± 1.90 and 20.54 ± 5.16 g per 
100-mg muscle, without and with Cr respectively. Corrected peak force during the 
recovery period was 3.25 ± 0.25 and 6.37 ± 2.40 g per 100 mg muscle, without and with 
Cr, respectively. Hypertrophied EDL’s produced 21.00 ± 1.66 g per 100 mg muscle 
without Cr and 15.34 ±  3.33 g per 100 mg with Cr. In the recovery period hypertrophied 
EDL’s produced 9.13 ± 3.07 and 8.85 ± 1.01 g per 100 mg muscle, with and without Cr, 
respectively. Soleus surgical controls generated 22.51 ± 5.38 and 23.85 ± 2.34 g per 
100-mg muscle with and without Cr respectively. Hypertrophied soleus muscles
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generated only 14.58 ±  3.21 and 7.01 ± 1.36 g per 100-mg muscle with and without Cr 
respectively. The trend continued in the second stimulatory period as surgical controls 
generated 12.90 ± 3.59 and 11.57 ± 2.90 g, with and without C r respectively. Compared 
to 6.73 ± 1.25 and 5.00 ± 0.98 g per 100 mg respectively. This may due, in part to scar 
and connective tissue in the soleus that could not be separated out from the muscle fibers. 
The presence o f scar tissue, connective tissue, or the hydration status o f the muscle may 
effect the size o f  the hypertrophied soleus muscles and decrease the force per unit 
muscle. No difference was seen in the EDL, which may be due to the “cleanliness” of 
the ablation surgery.
Tension for First 30 Seconds 
Force o f the contractions was calculated every 10 s. The force o f the contractions 
was then used to calculate the fetigue curve (Figures 9,10,11,12) and the area under that 
curve. Areas for the first 30 s o f stimulation were compared for the initial and second 
stimulation periods (Table 5). No difference in the tension produced was seen due to 
supplement. Differences were observed between the hypertrophied and surgical control 
muscles and between initial and recovery stimulation periods (Figures 13,14). 
Hypertrophied muscles produced significantly greater tension (828.57 ±  79.45 g) than 
surgical controls (448.53 ± 54.58 g). All muscles produced significantly more tension in 
the initial simulation (941.64 ± 70.85 g) than in the second period o f stimulation (336.02 
± 44.41 g). The hypertrophied EDL’s produced about twice as much tension as the 
surgical controls, 1143.98 ±  246.84 g and 1224.12 ± 151.27 g with and without Cr 
respectively, compared to 555.52 ± 139.06 and 601.07 ± 66.59 g, with and without Cr 
respectively. Hypertrophied EDL’s in the second stimulation period produced a tension.
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484.29 ± 174.59 g and 363.97 ±  65.48 g, with and without Cr respectively for the first 30 
seconds, compared to 154.24 ± 62.63 g and 74.44 ± 9.26 g, with and without Cr 
respectively, in the surgical controls. The hypertrophied soleus muscles also generated 
greater tension in the first 30 seconds o f  the initial period, 1148.15 ± 17.34 g and 1219.58 
±  277.71 g with and without Cr, respectively than the controls, 815.02 ± 220.19 g and 
677.72 ± 191.20 g, with and without Cr respectively. In the second stimulation period 
hypertrophfed soleus muscles produced 444.85 ± 129.15 g and 599.45 ±  206.07 g, with 
and without Cr respectively. The surgical controls produced 290.38 ± 71.87 and 276.57 
± 78.29 g with and without Cr respectively.
Percent Recovery o f Tension 
The soleus muscles in general demonstrated a higher degree o f recovery than the 
EDL (44.40 ± 5.69% to 28.70 ± 4.12%); similar to the recovery o f  peak force. Overall 
the non-supplemented, non-hypertrophied animals showed a significantly smaller percent 
recovery than all other groups, 21.57 ±  3.2% compared to 43.35 ±  9.3% for the non- 
hypertrophied, Cr group, 37.09 ±  6.3% for the hypertrophied, non-supplemented group, 
and 44.19 ±  7.4% for the hypertrophkd, Cr group. In this case Cr has a positive effect, 
by increasing the percent recovery within the surgical controls. No difference was seen 
in the hypertrophied muscles, which suggests that the training effect demonstrated by the 
hypertrophied muscles was greater than the effect Cr has on skeletal muscle. Within the 
EDL the surgical controls recovered to 33.7 ± 11.3% and 12.6 ±  1.0% with and without 
Cr respectively. The hypertrophied EDL’s recovered to 37.4 ± 9.7% and 31.1 ± 5.4% 
with and without Cr respectively. The soleus surgical controls recovered to 53.0 ± 15.7%
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and 30.6 ±  3.8% with and without Cr respectively. While the hypertrophied soleus 
muscles recovered to 36.8 ± 9.8% with Cr and 57.2 ±  13.0% without Cr.
Tension for the Second 30 Seconds 
Area for the second 30 seconds o f  stimulation (Table 6) showed that same 
relationship as that o f  the first 30 seconds (Figures 15,16). Results indicated that the 
hypertrophied muscles produced significantly greater tension in the second 30 second o f 
stimulation than surgical controls (382.10 ± 42.25g and 166.54 ± 26.08 g, respectively). 
The muscles also generated significantly greater tension in the initial period of 
stimulation when compared to the recovery period (399.32 ± 39.39 g and 150.62 ± 27.41 
g, respectively). In the initial period o f  stimulation the hypertrophied EDL’s produced 
greater tension, 483.58 ± 135.78 g with Cr and 566.36 ±  105.83 g without Cr, than the 
non-hypertrophied EDL’s, 189.73 ± 65.67 g with Cr and 146.37 ± 22.32 g without Cr. Cr 
supplementation had no effect on the tension generated during the second 30 seconds o f 
stimulation. Tension in the initial period o f stimulation was greater than the tension 
generated in the second stimulation period in all cases. In the second period of 
stimulation the hypertrophied EDL’s produced 218.66 ± 86.66 g with Cr and 213.14 ± 
56.83 g without Cr. The surgical controls produced 79.93 ±  29.15 g with Cr and 21.95 ± 
5.18 g without Cr in the second stimulation period. In the soleus muscles the 
hypertrophied muscles generated 439.03 ± 88.49 g with Cr and 613.00 ± 141.55 g 
without Cr in the initial stimulation period. Surgical controls generated 371.19 ±  104.01 
g with Cr and 374.84 ± 82.61 g without Cr. In the second stimulation period surgical 
controls recovered to generate 87.71 ±  24.55 g with Cr and 60.58 ± 17.65 g without Cr.
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The hypertrophied muscles generated significantly greater force, although no difference 
was seen between supplemental controls and Cr groups. Hypertrophied soleus muscles 
produced 191.68 ±62.53 g with Cr and 331.33 ± 161.15 g without Cr.
Time to One-Half Peak Force 
Time to one-half peak force (Tl/2) for each animal during each stimulation period was 
calculated from a regression equation, Y = aX^b, where Y is equal to time in seconds and 
X  is equal to force in gran^. Time to one-half peak force (Tl/2) (Table 7, Figures 17,18), 
along with percent recovery o f tension, generated the only significant results regarding 
supplementation. Results are similar to peak force and tension with regard to initial vs. 
second stimulation, hypertrophy vs. non-hypertrophy, and soleus vs. EDL. T l/2 was 
significantly greater in the initial stimulation period, 16.23 ± 2.03 s, compared to 10.98 ±
1.84 s for the second period. Hypertrophied muscles had significantly larger T l/2 ’s than 
non-hypertrophied muscles, 17.56 ±2.51 s and 9.66 ±0.91 s, respectively. Soleus 
muscles exhibited significantly prolonged T l/2 ’s when compared to EDLs, 17.19 ± 2.53 
s to 10.02 ± 0.92 s respectively. Results o f T l/2  suggest that Cr supplementation may 
result in a decrease time to fetigue. Non-supplemented muscles exhibited a  T l/2  of 16.92 
±  2.59 s, while Cr muscles had a significantly lower T l/2 o f 10.29 ± 0.78 s. An analysis 
o f  the significant muscle x supplement interaction revealed that non-supplemented soleus 
muscles had significantly higher Tl/2s (23.34 ± 4.67 s) than Cr supplemented soleus 
muscles (11.04 ±  1.07 s) and both supplemented and non-supplemented EDLs (9.54 ± 
1.13 s and 10.50 ± 1.46 s respectively). Further analysis o f  the significant supplement x 
surgery interaction indicated that non-supplemented, hypertrophied muscles resisted 
fatigue to a  greater extent (24.28 ± 4.51 s) than the non-supplemented non-hypertrophied
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group (9.56 ±  1.57 s) and both the Cr supplemented surgical control and Cr supplemented 
hypertrophied groups (9.75 ± 0.97 s and 10.83 ± 1.23 s respectively).
This result is in contrast too popularly held notions that Cr should increase time to 
fatigue. Fitts (1994) suggests one explanation o f  this result may be due to ADP and Pi 
level, as well as the ATP/ADP ratio within the cell. Force o f contraction is regulated in 
large part by Ca^\ which is released from the SR upon depolarization and taken back up 
by ATP dependent Ca^^-punçs. Pi and the ATP/ADP ratio may influence these calcium 
pumps. If  ATP levels are limited, not all Ca^^ is removed from the cell. The pumps do 
not have the energy, ATP, to continue the removal o f Ca^^. I f  Ca^  ^is still present in the 
cell, complete relaxation can not occur and a summation effect takes place. If  PCr is 
available ATP will be regenerated, and the ATP/ADP ratio will remain high, and Pi will 
be lower. A higher ATP/ADP ratio may allow the Ca^^ pumps to remove more Ca^^ from 
the cell, allowing for greater relaxation, and reducing the summation effect. A reduction 
in the summation effect would therefore decrease the force o f  contraction and give the 
appearance o f a fester time to fetigue.
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CONCLUSION
Hypertrophy, may result in a training effect that is more pronounced than the 
effect o f  Cr supplementation, which would o g la in  why little difference was observed in 
the hypertrophied muscles. With hypertrophied EDLs 57% larger and hypertrophied 
soleus’ 165% larger than controls, the effect o f Cr may have been overshadowed. 
Previous human studies have shown Cr to have an ergogenic effect with much smaller 
gains in muscle size. Cr supplementation had no effect on the size or performance o f  the 
hypertrophied muscles, with the exception o f T l/2, as discussed previously. Cr 
supplementation may have an effect on the control muscles, however this effect is not 
statistically significant. There was a slight difference in the percent recovery o f  peak 
force and tension within the EDL surgical controls between the non-supplemented and Cr 
groups, such that the Cr group recovered to a greater extent than the non-supplemented 
group (Tables 3 & 5). There was also a difference in the soleus surgical controls, 
although not as large as the EDL. Non-supplemented, surgical control soleus muscles 
recovered to a lesser extent in both peak force and tension than Cr supplemented, control 
muscles.
Dietary Cr supplementation had no effect on muscular hypertrophy and
electrically stimulated performance in rat skeletal muscle. It is possible, however
unlikely, that rat skeletal muscle is affected differently than human skeletal muscle by Cr
supplementation. Human studies have yielded mixed results as to Cr and it effect on
33
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performance. Human athletic performance is subject to numerous external and internal 
factors, including, but not limited too, time o f day, diet, motivation o f  the individual, 
environment, training state and simply how one feels that day. Dietary supplementation 
o f Cr may have more o f a psychological effect than any actually physiological effect.
It has been proposed that Cr may have an effect on Ca^^ removal within the 
muscle cell but without measurements of intracellular Ca^^, ATP, ADP, Pi, Cr and PCr 
no firm conclusions can be drawn firom this study. Future studies should focus on this 
possible relationship, to determine if increased intracellular Cr does assist in Ca^^ 
removal
These findings are consistent with others who have reported that peak force, 
power or torque was unaffected by supplementation (Ôôpik, et a l  1999; Cooke and 
Bames, 1997; Cooke, Grandjean and Barnes, 1995).
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Table 1
Change in Body Weight Over 5 Week Treatment Period. Post Ablation Surgery
Surgical EDL Soleus
Supplement Conrol Hypertrophy Hypertrophy
Control 211.0 (8.2)g 218.0 (6.3)g 221.5 (6.5)g
n = 6 n =  6 n = 6
Creatine 210.5 (8-9)g 205.0 (7.2)g 175.8 (6.5)*g
n = 6 n = 6 n = 6
* Significantly different from all others, p < 0.05. 
Values presented and mean (SEM)
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Table 2
Muscle Size. Following 5 Week Treatment Period
EDL EDL Soleus Soleus
Supplement Surgical Control Hypertropy Surgical Control Hypertrophy
Control 188.5 (6.4)mg 272.8 (24.5)*mg 176.9 (7.6)mg 504.8 (77.1)**mg
n = 12 n = 12 n = 12 n= 12
Creatine 177.1 (6.2)mg 299.3 (38.5)*mg 172.9 (7.7)g 419.2 (64.3)**mg
n =  12 n = 12 n = 12 n = 12
* Significantly different from all others, p < 0.05.
** Significantly different from all others, p < 0.05. 
Values presented as mean (SEM)
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Table 3
Peak Force. Generated bv Electrical Stimulation
EDL
Con-Con Cort-Cr Hyp-Con Hyp-Cr
Initial Stim 
Recovery Stim 
% Recovery
41.1 (3.66) g 
n = 5 
6.20 (0.69) g 
n = 5 
15.4(1.5)
36.01 (9.40) g 
n = 6 
10.81 (3.98) g 
n = 6 
38.7(13.5)
54.18 (4.27)* g 
n = 6 
22.67 (2.16)" g 
n = 6 
43.2 (5.6)
51.16 (826)* g 
n = 6 
31/18 (9.87)" g 
n = 6 
57.5(14.5)
Soleus
Con-Con ConCr HypCon Hyp-Cr
Initial Stim 
Recovery Stim 
% Recovery
41.61 (3.23) g 
n = 5 
19.93 (4.88) g 
n = 5 
45.7 (9.1)
37.11 (9.13) g 
n = 6 
21.23 (6.03) g 
n = 6 
60.0 (6.6)
48.58 (10.35)* g 
n = 6 
36.16 (10.18)" g 
n = 6 
85.0(15.7)
56.38 (6.16)* g 
n = 6 
30.51 (7.68)" g 
n = 6 
54.9(14.0)
Con-Con: Surgical control, no creatine 
Con-Cr: Surgical control, creatine
Hyp-Con: Hypertrophy, no creatine 
Hyp-Cr Hypertrophy, creatine
* Significantly different from all surgical controls in initial stim, p < 0.05.
“ Significantly different from all surgical controls in recovery stim, p < 0.05. 
** Initial stim significantly different from recovery in all cases, p < 0.05.
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Table 4
Size Corrected Peak Force
EDL
Con-Con Con-Cr Hyp-Con HypCr
Initial Stim 
Recovery Stim
22.04 (1.90) g 
n = 5 
3.25 (0.25) g  
n = 5
20.54 (5.16) g 
n = 6 
6.37 (2.40) g 
n = 6
21.00 (1.66) g
n = 6  
8.85(1.01) 
n = 6
15.34 (3.33) g 
n = 6 
9.13 (3.07) g 
n = 6
Soleus
Con-Con Con-Cr HypCon Hyp-Cr
Initial Stim 
Recovery Stim
23.85 (2.34)* g 
n = 5 
11.57 (2.90)" g 
n = 5
22.51 (5.38)* g 
n = 6 
12.90 (3.59)" g 
n = 6
7.01 (1.36) g 
n = 6  
5.00 (0.98) g 
n = 6
14.58 (3.21) g 
n = 6 
6.73 (1.25) g  
n = 6
Con-Con: Surgical control, no creatine 
Con-Cr: Surgical control, creatine
Hyp-Con: Hypertrophy, no creatine 
Hyp-Cr: Hypertrophy, creatine
* Significantly different from hypertrophied soleus in initial stim, p < 0.05.
“ Significantly different from hypertrophied soleus in recovery stim, p < 0.05. 
** Initial stim significantly different firom recovery in all cases, p < 0.05.
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Table 5
Tension Generated for the First 30 Seconds o f Electrical Stimulation
EDL
Con-Con Con-Cr Hyp-Con Hyp-Cr
Initial Sitm 601.07 (66.59) g 555.52 (139.06) g 1224.12 (151.27)* g 1143.98 (246.84)* g
n = 5 n = 6 n = 6 n = 6
Recovery Stim 74.44 (9.26) g 154.24 (62.63) g 363.97 (65.48)" g 484.29 (174.59)" g
n =  5 n = 6 n = 6 n =  6
% Recovery 12.6(1.0) 33.7(11.3)# 31.1 (5.4) 37.4 (9.7)
Soleus
Con-Con Con-Cr Hyp-Con Hyp-Cr
Initial Stim 677.72 (191.20) g 815.02 (220.19) g 1219.58 (277.71)* g 1148.15 (147.34)* g
n = 5 n = 6 n = 6 n = 6
Recovery Stim 276.57 (78.29) g 290.38 (71.87) g 599.45 (206.07)" g 444.85 (129.15)" g
n =  5 n = 6 n = 6 n = 6
% Recovery 30.6 (3.8) 53.0(15.7)# 57.2(13.0) 36.75 (9.8)
Con-Com Surgical control, no creatine 
Con-Cr Surgical control, creatine 
Hyp-Con: Hypertrophy, no creatine 
Hyp-Cr: Hypertrophy, creatine
* Significantly different from all surgical controls in initial stim, p < 0.05.
“ Significantly different from all surgical controls in recovery stim, p < 0.05. 
** Initial stim significantly different from recovery in aU cases, p < 0.05.
# Significantly different from surgical control, no creatine
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Table 6
Tension Generated for the Second 30 Seconds of Electrical Stimulation
EDL
Con-Con Con-Cr Hyp-Con Hyp-Cr
Initial Stim 
Recovery Stim
146.37 (22.32) g 
n = 5 
21.95 (5.18) g  
0 = 5
189.73 (65.67) g 
n = 6 
79.93 (29.15) g 
n = 6
566.36 (105.83)* g 
n = 6 
213.14 (56.83)" g 
n = 6
483.58 (135.78)* g 
n = 6
218.66 (86.66)" g
n = 6
Soleus
Con-Con Con-Cr HypCon Hyp-Cr
Initial Stim 
Recovery Stim
374.84 (82.61) 
n = 5 
60.58 (17.65) g  
n = 5
371.19 (104.01) g 
n = 6 
87.71 (24.55) g 
n = 6
613.00 (141.55)* g 
n = 6 
331.33 (161.15)" g 
n = 6
439.03 (88.49)* g 
n = 6 
191.68 (62.53)" g 
n = 6
Con-Con: Surgical control, no creatine 
Con-Cr: Surgical control, creatine 
Hyp-Con: Hypertrophy, no creatine 
Hyp-Cr: Hypertrophy, creatine
* Significantly different from all surgical controls in initial stim, p < 0.05.
“ Significantly different from all surgical controls in recovery stim, p < 0.05. 
** Initial stim significantly different from recovery in all cases, p < 0.05.
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Table 7
Time to One-Half Peak Force. Calculated From the Regression Equation Y = aX^b
EDL
Con-Con Con-Cr Hyp-Con Hyp-Cr
Initial Stim 
r for Y = aX^b
Recovery Stim 
r for Y = aX^b
7.36 (0.53) s 
-0.949 
n = 5 
4.98 (0.43) s 
-0.956 
n = 5
8.89(1.46)$  
-0.919 
n = 6 
7.93(1.48)$  
-0.764 
n = 6
16.89 (2.57) s 
-0.909 
n =  6 
12.78 (3.88) $ 
-0.930 
n = 6
14.69(3.15) 
-0.925 
n = 6 
6.65(1.24)5 
-0.981 
n = 6
Soleus
Con-Con Con-Cr HypCcwi Hyp-Cr
Initial Stim 
rforY  = aX^b
R ecovay Stim 
r for Y = aX'H)
14.23 (2.45) s 
-0.880 
n = 5 
11.68 (5.34) s 
-0.928 
n = 5
15.03(1.80)3  
-0.893 
n = 6 
7.14(1.41)$  
-0.941 
n = 6
39.13(12.02)*$ 
-0.826 
n =  6 
28.31 (11.09)*$ 
-0.816 
n =  6
13.62(1.76)$ 
-0.911 
n = 6 
8.37(1.95)$ 
-0.927 
n = 6
Con-Con: Surgical control, no creatine 
Con-Cr: Surgical control, creatine
Hyp-Con: Hypertrophy, no creatine 
Hyp-Cr: Hypertrophy, creatine
Values presented as mean (SEM)
* Significantly different from all others, p < 0.05.
** Initial stim significantly different fipm recovery in all cases, p < 0.05.
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Figure 1
Structure of Creatine and Phosphocreatine
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Synthesis o f Creatine
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Figure 4
Urinary Creatinine
* Significantly different than non-supplement or control, p < 0.05.
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Figure 5
EDL Peak Force Produced
EDL-C-C: Surgical Control, No Creatine 
EDL-Cr-C: Surgical Control, Creatine 
EDL-C-H: Hypertrophy, No Creatine 
EDL-Cr-H: Hypertrophy, Creatine
*Significantly different from surgical controls in initial, p < 0.05. 
#Significantly different from surgical controls in recovery, p < 0.05. 
**Initial significantly different from recovery in all cases, p < 0.05.
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Figure 6
Soleus Peak Force Produced
Sol-C-C: Surgical control. No Creatine 
Sol-Cr-C: Surgical control, Creatine 
Sol-C-H; Hypertrophy, No Creatine 
Sol-Cr-H: Hypertrophy, Creatine
* Significantly different fi’om surgical controls in initial, p <0.05. 
#Significantly different firom surgical controls in recovery, p < 0.05. 
♦♦Initial significantly different from recovery in all cases, p < 0.05.
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Figure 7
EDL Size Corrected Peak Force
C-C: Surgical Control, No creatine 
C-Cr: Surgical Control, Creatine 
H-C: Hypertrophy, No creatine 
H-Cr: Hypertrophy, Creatine
♦♦Initial significantly different firom recovery, p < 0.05.
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Soleus Size Corrected Peak Force
30 - 
25 - 
^  20 -I 15^ 
10 4 
5 
0
I □  Initial 
g  Recovery
L
C-C C-Cr PTC 
Group
BtCt
Figure 8
Soleus Size Corrected Peak Force
C-C: Surgical control. No Creatine 
C-Cr: Surgical control. Creatine 
H-C: Hypertrophy, No Creatine 
H-Cr: Hypertrophy, Creatine
♦Significantly different from hypertrophy in initial, p < 0.05. 
#Significantly different from hypertrophy in recovery, p < 0.05. 
♦♦Initial significantly different from recovery in all cases, p < 0.05.
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Figure 9
EDL Initial Stim ulation Fatigue Curve
Con-C: Surgical control. No creatine 
Con-Cr: Surgical control. Creatine 
Hyp-C: Hypertrophy, No creatine 
Hyp-Cr: Hypertrophy, Creatine
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Figure 10
Soleus Initial Stimulation Fatigue Curve
Con-C: Surgical control. No creatine 
Con-Cr: Surgical control, Creatine 
Hyp-C: Hypertrophy, No creatine 
Hyp-Cr: Hypertrophy, Creatine
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Figure 11
EDL R ecovery Stim ulation Fatigue Curve
Con-C: Surgical control. No creatine 
Con-Cr: Surgical control. Creatine 
Hyp-C: Hypertrophy, No creatine 
Hyp-Cr: Hypertrophy, Creatine
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Figure 12
Soleus Recovery Stimulation Fatigue Curve
Con-C: Surgical control. No creatine 
Con-Cr: Surgical control. Creatine 
Hyp-C: Hypertrophy, No creatine 
Hyp-Cr: Hypertrophy, Creatine
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Figure 13
EDL Tension o f  First 30 Seconds
C-C: Surgical control. No creatine 
C-Cr: Surgical control, Creatine 
Hyp-C: Hypertrophy, No Creatine 
Hyp-Cr: Hypertrophy, Creatine
* Significantly different from surgical controls, in initial, p < 0.05. 
#Significantly different from surgical controls, in recovery, p < 0.05. 
♦♦Initial s ig i^can tly  different from recovery in all cases, p < 0.05.
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Soleus Tension 0-30 Seconds
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Figure 14
Soleus Tension o f First 30 Seconds
C-C: Surgical control. No creatine 
C-Cr: Surgical control. Creatine 
Hyp-C: Hypertrophy, No Creatine 
Hyp-Cr: Hypertrophy, Creatine
♦Significantly different from surgical controls, in initial, p < 0.05. 
#Significantly different fit>m surgical controls, in recovery, p < 0.05. 
♦♦Initial significantly different from recovery in all cases, p < 0.05.
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EDL Tension 30-60 Seconds
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Figure 15
EDL Tension o f Second 30 Seconds
C-C: Surgical control. No creatine 
C-Cr: Surgical control. Creatine 
Hyp-C: Hypertrophy, No Creatine 
Hyp-Cr: Hypertrophy, Creatine
♦Significantly different from surgical controls, in initial, p < 0.05. 
#Significantly different from surgical controls, in recovery, p < 0.05. 
♦♦Initial significantly different from recovery in all cases, p < 0.05.
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Figure 16
Soleus Tension o f  Second 30 Seconds
C-C: Surgical control. No creatine 
C-Cr: Surgical control. Creatine 
Hyp-C: Hypertrophy, No Creatine 
Hyp-Cr: Hypertrophy, Creatine
♦Significantly different from surgical controls, in initial, p < 0.05. 
#Significantly different from surgical controls, in recovery, p < 0.05. 
♦♦Initial significantly different from recovery in all cases, p < 0.05.
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Figure 17
EDL Time to One-Half Peak Force
Con-C: Surgical control. No creatine 
Con-Cr: Surgical control. Creatine 
Hyp-C: Hypertrophy, No Creatine 
Hyp-Cr: Hypertrophy, Creatine 
**No significant differences between groups.
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Figure 18
Soleus Time to One-Half Peak Force
Con-C: Surgical control, No creatine 
Con-Cr: Surgical control. Creatine 
Hyp-C: Hypertrophy, No Creatine 
Hyp-Cr: Hypertrophy, Creatine 
♦Significantly different from all others, p < 0.05.
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FOR COKMirrBB P8B ONLY 
UNIVERSITY or NEVAOX, LAS VE6A8
PROTOCOL FOR ANIMAI. CARE AND USE - PROTOCOL NUMBER R701-10<?q-l&l
TITLE: ThP o f  d i e t a r y  c r e a t in e  su p p le m e n ta t io n  on  c o m p en sa to r y  m u s c le
h yp ertrop h y  and p erform an ce c h a r a c t e r i s c l e s  o f  s p c c l t l c  t l b e r  ty p e s
COMMITTEE ACTION:
  RECOMMENDED FOR APPROVAL AS SUBMITTED, DATE: 15 O ct 98
RECOMMENCED FOR APPROVAL MITE MODIFICATIONS*
DEFERRED FOR ADDITIONAL INFORMATION, DATE: ____________
RETURNED TO INVESTIGATOR FOR REVISION, DATE:
  DISAPPROVED, DATE: _______ I / / ^ / f
" U ?  /  ^  DATE
CHAIRMAN ^ ' DATE
* MODIFICATIONS REQUIRED:
/ ;
On Supplem ent Form 2 . q u e s t io n  # 3 b . ,  put t h a t  th e r e  w i l l  b e  su p p lem e n t  
a n e s t h e s ia  g iv e n  as n e c e s s a r y  and in d ic a t e  th e  d o sa g e  (recom m ended  Im g/lO O g). 
P le a s e  su b m it a d d it io n  to  e i t h e r  Stan  H il ly a r d  or M arsha Moon b e f o r e  
p r o c e d u r e s  can  s t a r t .
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OFFICE USE ONLY: Protocol Na:_ 
Date received:
UNIVERSITY OF NEVADA, LAS VEGAS 
PROTOCOL FOR ANIMAL CARE AND USE 
(form most be typewritten)
1. TITLE: The effect of dietary creatine supplementation on compensatory muscle hypertrophy and 
performance diaracteristics of specific fiber types.
2. PRINCIPAL INVESTIGATOR/COURSE DIRECTOR:
NAME & TITLE: Dr. Carl Reiber
DEPARTMENT: Biological Sciences
OFFICE PHONE: 895-1549 EMERGENCY PHONE: 896-5104
3. OTHER RESPONSIBLE PERSONS:
NAME RESPONSIBILITY OFFICE PHONE EMERGENCY PHONE
Robert Young 895-1582 454-0001
John C. Young Ph.D. (Co-P.I.) 895-4626 898-8845
4. PROTOCOL STATUS: X NEW __MODIFICATION _CONTINUATION
RESEARCH TEACHING EXHIBITION
START DATE: 11-1-98 ANTICIPATED COMPLETION DATE: 2-1-99
5. FUNDING SOURCE: X DEPARTMENT X OTHER INTRAMURAL SOURCE 
 EXTRAMURAL, SPECIFY SOURCE: URGFC
6. CATEGORY OF ETHICAL CONCERN APPLICABLE TO THIS PROTOCOL: C 
(SEE TABLE 1 FOR EXPLANATION OF CATEGORIES, IF MORE THAN ONE 
CATEGORY APPLIES, USE THE HIGHEST)
7. WILL THE PROJECT OR EXERCISE INVOLVE EXPOSURE OF ANIBfALS OR 
ANIMAL HANDLERS TO:
BIOHAZARDS? X NO___YES. IF YES, SPECIFY;__________
RADIOISOTOPES? X NO___YES. IF YES, SPECIFY:__________
CARCINOGENS? X NO___YES. IF YES, SPECIFY:__________
TOXIC CHEMICALS? X NO___YES. IF YES, SPECIFY:__________
IF ANY ITEM ANSWERED YES, COMPLETE AND ATTACH SUPPLEMENT 
FORM 1
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8. CHECK ALL ITEMS WHICH APPLY TO THIS PROJECT:
X Blood and/or tissue collection X Survival surgery
 Antibody production and collection X Non-survival surgery
Behavioral studies X Aseptic surgery
_Prolonged physical restraint__________ __Multiple surgeries on the same animal
 Food or water deprivation
 Environmental extremes X Alleviated pain
X Electrical stimuli_____________________Unalleviated pain
 Induction of trauma X Anesthetics used
 Work to be done off campus__________ __Immobilizing agents without anesthesia
 Field studies
9. ANIMAL REQUIREMENTS:
SPECIES STRAIN SEX AGEAVT TOTAL NO.
Rats Sprague-Dawley Male 140 - 160 g 36
USE RATE DURATION OF STAY SOURCE
4 - 6  weeks Standard Vendor
10. LOCATION OF ANIMAL HOUSING AND USE AREAS:
ANIMAL HOUSING FACILITY: Animal Care Facility - White Hall - UNLV_________
WILL ANIMALS BE REMOVED FROM THE HOUSING FACILITY FOR USE 
ELSEWHERE? NO X  YES. IF YES, SPECIFY LOCATION(S)
(BLDG *  ROOM NO.): Bigalow Health Sciences. Rm 119_______________
11. IS SURGERY INVOLVED IN THE PROPOSED PROJECT?
_N O  X YES. IF YES, COMPLETE AND ATTACH SUPPLEMENT FORM 2
12. ARE STRESSFUL OR PAINFUL PROCEDURES, OTHER THAN SURGERY, PART OF
THIS PROJECT? X N O  YES. IF YES, COMPLETE AND ATTACH SUPPLEMENT
FORM 3.
13. ARE PROLONGED (MORE THAN A FEW HOURS) PHYSICAL RESTRAINT 
mOCEDURES PART OF THIS PROJECT? X NO __YES. IF YES, COMPLETE 
AND ATTACH SUPPLEMENT FORM 4.
14. WILL ANIMALS BE EUTHANmZED? NO X YES. IF YES. LIST THE 
METHOD(S) (BY SPECIES) AND, IF APPLICABLE, THE DOSE AND ROUTE OF 
ADMINISTRATION:
Pentobarbital Sodium. Intercardial injection upon completion of electrical stimulation procedure. 
(Animals will be anesthetized throughout the electrical stimulation procedure.)
IS. WILL ANIMALS BE AUV E ATTHE END OF THE PROJECT? X NO YES. IF
YES, HOW WILL THEY BE USED?
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16. ARE THERE ANY SPECIAL REQUIREMENTS FOR ANIMAL HOUSING, DIETS,
RESTRAINT, OR PROCEDURES FOR DISPOSAL? NO X YES. IF NO, ANIMALS
WILL BE MAINTAINED ACCORDING TO THE STANDARD OPERATING 
PROCEDURES. IF YES, PROVIDE (AN) EXPLANATION(S) FOR EACH PARAMETER 
INVOLVED (E G ., LIGHTiDARK CYCLES, HUMIDITY, AMBIENT TEMPERATURE 
CAGING, BEDDING, DIETS, AND SO FORTH):
In addition to a normal diet, animals will be fed a diaary supplement (Jello squares) which may 
or may not contain the nutritional supplement creatine. Half the rats will receive creatine and 
half will not
17. RESEACH OR TEACHING PLAN: IN SUFFICIENT DETAIL TO PERMIT 
EVALUATION BY MEMBERS OF THE INSTITUTIONAL ANIMAL CARE AND USE 
COMMITTEE (lACUC), ANSWER THE FOLLOWING QUESTIONS (USE 
CONTINUATION PAGES IF NECESSARY):
a. WHAT IS (ARE) THE OBJECTIVE(S) AND POTENTIAL SIGNIFICANCE OF 
THE ACTIVITIES INVOLVING ANIMAL USE?
Creatine is a popular nutritional supplement used ly  athletes to enhance performance. 
Creatine is an amino acid obtained from meat and fish in the diet and synthesized from 
methionine, glycine, and arginine. Creatine is phospAorylated, via creatine kinase, to 
pbosphotzeadne. PhoqAocreatine is a high energy compound that supports the re-synthesis of 
ATP during the initial stages of intense muscular activity. Studies have shown the creatine 
supplementation leads to increased phosphocreatine stores within skeletal muscles. However, 
these studies have yielded mixed reâihs as to creatine’s effect on muscular hypertrophy and 
intense muscular activity. The focus o f this study is to investigate the effect o f creatine 
supplementation on compensatory hypertrophy and maximal muscular activity.
b. SPECIFICALLY, WHY ARE LIVE ANIMALS REQUIRED FOR THIS 
PROJECT RATHER THAN NON ANIMAL ALTERNATIVES?
Rats were selected as the model for this study because qmergistic ablation results in 
relatively rapid muscle hypertrophy, wfaidi is similar to that achieved ly  humans over a 
considerably longer time period with high resistance weight training. In addition, rat skeletal 
muscles of nearly homogenous muscle fiber types permit the determination o f creatine’s effect in 
fest and slow twitch muscles. Computer simulations were considered but were rejected because 
the absence o f data regarding the effects of creatine on performance measures o f specific fiber 
types precluded this approach.
c. IN ACCORDANCE WITH TEK REQUIREMENTS OF THE FEDERAL 
ANIMAL WELFARE ACT (SECTION L3:(DX1)(II), PLEASE LIST WHAT NON­
ALTERNATIVES YOU CONSIDERED USING, HOW YOU DETERMINED THAT 
THEY ARE NOT SUITABLE NOR THAT OTHER ALTERNATIVES ARE NOT 
AVAILABLE, AND YOUR SOURCES OF INFORMATION ABOUT THE 
AVADLABIUTY OF ALTERNATIVES.
Computer simulations were considered, but the absence of data concerning the effects of 
creatine on hypertrophy and performance of specific fiber types does not permit use of this 
alternative. The use ofhuman subjects is impractical due to the relatively slow rate of muscular 
hypertrophy, and the in ability to measure poformaoce of specific fiber types. Infixmadon was 
(ttained from literature searches o f the national library of medicine, utilizing Medline through 
PubMed, with the k^nvords (zeatine, muscle hypertrophy and computer simulation. Information 
was also obtained fixxn previous research experience.
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d. WHY IS (ARE) THE ANIMAL MODEL(S) YOU ARE PROPOSING TO USE THE
MOST APPROPRIATE MODEL(S) FOR ACHIEVING THE OBJECFIVES OF THIS 
PROJECT?
Substantial literature attests to the viability o f synergistic muscle ablation as a method of 
producing compensatory muscle hypertrophy. The relatively rapid rate of hypertrophy, in rats, 
ensures that the objectives of this project can be accomplished in a reasonable time frame. Also, 
rats will willingly ingest a palatable diet containing nutritional supplements.
e. WHAT ARE THE REASONS FOR REQUIRING THE NUMBER OF ANIMALS
REQUESTED?
The number of animals is the minimum number judged to be necessary to demonstrate 
statistical differences in muscular hypertrophy and performance characteristics o f individual fiber 
types.
£  WHAT ARE THE SPECIFIC PROCEDURES YOU ARE PROPOSING TO USE
WHICH WILL INVOLVE OR EFFECT THE ANIMALS?
See attached page.
18. CHECK ALL APPLICABLE ITEMS:
INSTRUCTIONS FOR DISPOSITION INSTRUCTIONS FOR DISPOSITION 
OF SICK OR INJURED ANIMALS OF DEAD ANIMALS
XCALL INVESTIGATm XCALL INVESTIGATOR
 VETERINARIAN TO TREAT  VETERINARIAN TO TREAT
 EUTHANITIZE______________________ EUTHANITIZE
19. IF WILD OR EXOTIC SPECIES ARE TO BE USED: ARE SPECIAL PERMITS 
REQUIRED? X NO _ Y E S . IF YES, ATTACH A COPY OF APPLICABLE PERMITS 
OR PERMIT APPLICATIONS.
WILL ANIMALS BE OBSERVED, MANIPULATED, OR TRAPPED IN THE WILD?
X NO _ Y E S . IF YES, AND THEY HAVE NOT ALREADY BEEN ADDRESSED, 
DESCRIBE THE FIELD PROCEDURE(S) AND GIVE THE GEOGRAPHIC 
LOCATION(S) INVOLVED:
20. WILL ANY NONANESTHETIC SUBSTANCES BE INTRODUCED INTO THE 
ANIMALS AS PART OF THIS PROJECT (E.G., PHARMACOLOGICAL OR 
TOXICOLOGIC AGENTS, ANTIGENS, HORMONES, TUMOR CELLS, ETC.)? X NO
YES. IF YES. DESCRIBE:
SPECIES SUBSTANCE DOSE ROUTE FREQUENCY
IS ANY ANIMAL PAIN, DISTRESS, OR DISCOMFORT EXPECTED TO BE ASSOCIATED 
WITH INTRODUCTION OF THIS (THESE) SUBSTANCES?
X NO _ Y E S . IF YES, EXPLAIN:
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21. WILL BLOOD OR TISSUES BE COLLECTED FROM THE ANIMALS OTHER THAN 
DURING TERMINAL ANESTHESIA PROCEDURES? X NO YES. IF YES. 
DESCRIBE THE TECHNIQUES TO BE USED:
IF BLOOD IS TO BE COLLECTED REPEATEDLY, WHAT IS THE QUANTITY OF 
BLOOD TO BE COLLECTED AT EACH DRAW? HOW OFTEN WILL BLOOD
SAMPLES BE COLLECTED? , AND WHAT PROCEDURES, IF ANY, WILL BE
USED TO PREVENT ANEMIA?
22. ARE BEHAVIORAL STUDIES INVOLVED IN THIS PROJECT? X NO _ Y E S . IF 
YES, AND NOT PREVIOUSLY DESCRIBED, PROVIDE A DESCRIPTION OF ALL 
METHODS AND PROCEDURES TO BE USED, OR WTTH, THE ANIMALS 
(INCLUDING ANY NUTRITIONAL DEMHVATION OR APPLICATION OF NOXIOUS 
STIMULI) AND INDICATE THE DURATION OF SUCH STUDIES:
23. JUSTIFICATION: THIS SECTION IS REQUIRED FOR ANY PROJECT IN WHICH
THERE IS A POTENTIAL FOR PAIN, DISTRESS, OR DISCOMFORT THAT CAIWOT 
BE ALLEVIATED. EXAMPLES OF SUCH PROJECTS INCLUDE INDUCED DISEASE 
STATES WHICH CAUSE SEVERE SYMPTOMS OR DEATH, SURGICAL STUDIES 
RESULTING IN SEVERE POST-OPERATIVE DISCOMFORT OR LOSS OF 
FUNCTION, THE USE OF SEVERE AND UNAVOIDABLE NOXIOUS STIMUU, AND 
SO FORTH. (USE CONTINUATION PAGES IF NECESSARY)
m. DESCRIBE WHAT UNALLEVIATED PAIN, DISTRESS, OR DISCOMFORT 
MAY BE EXPECTED TO BE ASSOCIATED WITH THIS PROJECT.
Post surgical pain, distress or discomfbit is not anticipated. Previous studies using this 
procedure have shown that animals were locomotive upon training consciousness, weight gain 
is normal, relative to control animals (Young, Kandarian AKurowski, 1992), and there was no 
gnawing of sutures or any similar behaviors that would indicate discomfort However if it 
determined by the PI, Co-Pl, or attending veterinarian that any animal is experiencing pain, 
Butorphand will be administered (0.1 -  O S mg/Kg) as prescribed by the attending veterinarian. 
The criteria for determining whether or not an animal is experiencing pain will be foilure to 
exhibit locomotion upon training consciousness, foilure to consume a normal diet and gnawing 
at sutures.
b. PROVIDE SPECIFIC JUSTIFICATION FOR THE NECESSITY OF ANY 
UNALLEVIATED PAIN, DISTRESS, OR DISCOMFORT LISTED IN THE 
PREVIOUS SECTION.
N/A
c. IS DEATH USED AS AN END-POINT IN THIS PROJECT?
X NO  YES. IF YES, EXPLAIN WHY SOME EARLIER END-POINT
CANNOT BE USED INSTEAD (PROVIDE OBJECTIVE SUPPORTING DATA):
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17. £ Ablatioa Procedure:
Rats will be anesthetized with pentobarbital sodium (Smg/IOOg body weight, ip).
Bilateral ablations will be performed. The lateral aspect of eadi hindlimb is shaved and a 
longitudinal incision is made through the skin and fescia along the lateral aspect of the tibia. To 
ablate the gastrocnemius and plantaris, the lateral and medial heads of the muscle are isolated 
with careful blunt dissection. The distal 2/3 o f the gastrocnemius and plantaris are removed with 
care not to disturb the vasculature and nerves associated with the soleus. To ablate the tibialis 
anterior the distal tendon is cut and the muscle removed in toto. The fescia and skin are then 
sutured distal to proximal with 5-0 silk. Rats will be monitored during recovery for signs of 
pain, distress or discomfort. Upon observation of pain, distress, or discomfort, by animal care 
staff attending veterinarian, or primary investigator, rats will be given Butorphanol as prescribed 
by the attending veterinarian.
Kandarian, S.C. & White, T.P. Mechanical deficit persists during long-term muscle hypertrophy. 
Jovnal o f Applied Physiology. 69(3): 861-867,19% .
Young, J.C., Kandarian, S.C. & Kurowski, T.G. Skeletal muscle glucose uptake following 
overload-induced hypotrophy. Life Sciences, 50: 1319-1325, 1992.
Creatine Supplementation:
In addition to a normal diet, animals will be feed a dietary supplement (Jello squares) 
which may or may not contain the nutritional supplement creatine monohydrate. The dose for 
animals recoving creatine monohydrate will be 300 mg/Kg body weight, once daily. This rate is 
equivalent to the recommended rate for human supplanentation. Unpublished lab results have 
shown creatine to have no significant effect on growth rate (see attached graph), or normal 
feeding patterns.
Electrical Stimalatioo Procedure:
Six weeks following the ablation surgery the rats will again be anesthetized witib 
pentobarbital sodium (5mg/100g body weight, ip). The sciatic nerve is exposed in the r^ o n  of 
the thigh (before the separation of die tibial and common peroneal branches) but not cut A 
dastre electrode is placed around the nerve, proximal to the bifurcation. The limb is fixed at the 
knee and ankle by steel pins inserted under the tibio-patellar ligament and the achilles tendons 
respectively. The muscle is tied via the distal tendon to a force transducer, connected to a Grass 
polygraph. The muscles are made to contract by stimulating the sciatic nerve electrically for two 
5 min periods separated ly  1 min of rest, with 500 ms trains of siqxamaximal voltage (60 -  80V) 
at a rate of 1 traWsec. Pulses are delivered at lOOHz, with each pulse in the train having a 
duration of 0.1 ms. Immediately after stimulation the muscles are isolated, freeze clamped and 
removed. Following the stimulation rats will be euthanitized by an intercardial injection of 
pentobarbital sodium, without being allowed to allowed to r%ain consciousness.
Young, i.e . & Balon, T.W. Role o f cUhyropyridine sensitive calcium channels in glucose 
transport in skeletal muscle. Life Sciences 61(3): 335-342, 1997.
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24. ASSURANCES:
m. PRINCIPAL INVESTIGATOR: I HAVE READ AND AGREE TO ABIDE BY
THE PROVISIONS OF THE UNLV POLICIES AND PROCEDURES HANDBOOK FOR 
THE USE OF LABORATOBV ANIMAI3i AND THE PUBLIC HEALTH SERVICE'S 
GUIDE FOR THE CARE AND USE OF LABORATORY ANIMAIS (COPIES OF THESE 
DOCUMENTS MAY BE OBTAINED FROM THE SUPERVISOR OF LABORATORY 
ANIMAL CARE SERVICES OR THE DIRECTOR OF LABORATORY ANIMAL 
MEDICINE). I WILL ADVISE THE UNLV INSTTTUIONAL ANIMAL CARE AND USE 
COMMITTEE IN WRITING OF ANY SIGNIFICANT CHANGES IN THE 
PROCEDURES DESCRIBED IN THIS PROTOCOL.
PRINCIPAL INVESTIGATOR/ TITLE/RANK DATE 
COURSE DIRECTOR
b. ALSO, I UNDERSTAND THAT "UNNECESSARILY DUPLICATIVE"
RESEARCH INVOLVING LABORATORY ANIMALS IS NOT PERMTITED BY THE 
FEDERAL ANIMAL WELFARE ACT AND HEREBY PROVIDE ASSURANCE THAT 
THE RESEARCH PROPOSED HEREIN DOES NOT, TO THE BEST OF MY 
KNOWLEDGE, HAVING REVIEWED THE RELEVANT LITERATURE, UN­
NECESSARILY DUPLICATE RESEARCH ALREADY REPORTED IN THE PUBLIC 
LITERATURE.
PRINCIPAL INVESTIGATOR/ TITLE/RANK DATE 
COURSE DIRECTOR
c. DEPARTMENT CHAIRMAN/DEAN: I HAVE REVIEWED THIS PROTOCOL
AND CERTIFY THAT THIS PROJECT IS SCIENTIFICALLY VALID AND THAT THE 
PERSONNEL CONDUCTING THE ANIMAL ASSOCIATED PROCEDURES ARE 
QUALIFIED AND TRAINED TO ACCOMPLISH THE PROCEDURES.
DEPARTMENT HEAD/DEAN DEPARTMENT DATE
d. SUPERVISOR, LABORATORY ANIMAL CARE SERVICES: I HAVE 
REVIEWED THIS mOTOCOL AND CERTIFY THAT RESOURCES FOR HOUSING 
AND HANDLING THE ANIMALS, INCLUDING FOR ANY SPECIAL RE 
QUIREMENTS SPECIFIED HEREIN, ARE AVAILABLE OR CAN BE EASILY 
OBTAINED.
SUPERVISOR, LABORATORY ANIMAL CARE, DATE
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«. VETERINARY ASSURANCE: THE TYPE AND AMOUNT OF ANAL
GESIC, ANESTHETIC, OR TRANQUHIZING DRUGS PROPOSED FOR USE IN 
THIS PROJECT ARE APPROPRIATE BY CURRENT PROFESSIONAL STANDARDS 
TO RELIEVE ANIMAL PAIN, DISTRESS, OR DISCOMFORT, EXCEPT AS 
JUSTIFIED ABOVE BY THE PRINCIPAL INVESTIGATOR. METHODS OF 
EUTHANASIA ARE COMPATIBLE WITH THE RECOMMENDATION OF THE 
AMERICAN VETERINARY MEDICAL ASSOCIATION'S PANEL ON 
EUTHANASIA REPORT fJAVMA. FEBRUARY 1 ,1986). FURTHERMORE, IF 
REQUIRED BY THE FEDERAL ANIMAL WELFARE ACT REGULATIONS, THE 
PRINCIPAL INVESTIGATOR HAS CONFERRED WITH ME DURING THE 
PREPARATION OF THIS PROTOCOL
DIRECTOR, LABORATORY ANIMAL MEDICINE DATE
(or ocher A ttcadlaf Veterinariaa)
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
72
UNIVERSITY OF NEVADA, IAS VEGAS 
PROTOCOL FOR ANIMAL CARE AND USE
SUPPLEMENT FORM 2
SURGICAL PROCEDURES 
(complete only if applicable - if not, discard)
1. a. Describe pre-operative care and selection procedures 
(including physical examinations, lab tests, and 
preconditioning procedures) :
N o  s p e c i a l  r e q u i r e m e n t s  b e y o n d  n o r m a l  c a r e  a n d  f e e d i n g .
b. List pre - operative and inter-operative medications 
and anesthetics:
Species Drug Dose/Kg Body Wt. Route Freq.
R a t s  P e n t o b a r b i t a l  5 m g / 1 0 0 g  b o d y  i p .  IX
S o d i u m  w e i g h t  i n j e c t i o n
If gas anesthetics will be used, describe the scavenging 
system for removal of extraneous anesthetic:
c. Who will administer the anesthetic? J . C .  Y o u n g ^
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2. Describe the surgical procedures, attaching additional 
sheets if necessary. (Sterile surgical techniques MUST 
be used in survival surgeries involving most animals; 
thus, a description of the procedures to be used to 
ensure asepsis should be provided. Multiple survival 
surgeries on a single animal are generally prohibited.
The only circumstances under which multiple survival 
surgeries may be justified are when they are related 
conq>onents of a single research project or to conserve 
rare and endangered species. Cost savings alone is not 
an adequate reason for perforsûng multiple survival 
surgeries.)
A b l a t i o n  s u r g e r i e s  w i l l  b e  p e r f o r m e d  i n  t h e  L A C F .  A  c l e a n  
o p e r a t i n g  f i e l d  w i l l  b e  e s t a b l i s h e d ,  s t e r i l e  g l o v e s  w i l l  b e  w o r n ,  
a  s t e r i l e  d r a p e  w i l l  b e  u s e d  a n d  a b s o r b e n t  p a d s  w i l l  b e  p l a c e d  
u n d e r  t h e  a n i m a l s  d u r i n g  s u r g e r y .  R a t s  w i l l  b e  a n e s t h e t i z e d  w i t h  
p e n t o b a r b i t a l  s o d i u m  ( 5 m g / 1 0 0 g  b o d y  w e i g h t ,  i p )  .  B i l a t e r a l  
a b l a t i o n s  w i l l  b e  p e r f o r m e d .  T h e  l a t e r a l  a s p e c t  o f  e a c h  h i n d l i m b  
i s  s h a v e d  i n  a n  a r e a  a p a r t  f r o m  t h e  s u r g i c a l  f i e l d .  T h e  s h a v e d  
a r e a  w i l l  b e  s c r u b b e d  w i t h  b e t a d y n e ,  p r i o r  t o  t h e  i n c i s i o n  b e i n g  
m a d e .  A l l  i n s t r u m e n t s  w i l l  b e  s t e r i l i z e d  i n  a  s t e a m  a u t o c l a v e  
p r i o r  t o  t h e  f i r s t  s u r g e r y .  A f t e r  t h e  f i r s t  s u r g e r y ,  a l l  
i n s t r u m e n t s  w i l l  b e  w a s h e d  a n d  w i p e d  w i t h  a l c o h o l .  A  l o n g i t u d i n a l  
i n c i s i o n  i s  m a d e  t h r o u g h  t h e  s k i n  a n d  f a s c i a  a l o n g  t h e  l a t e r a l  
a s p e c t  o f  t h e  t i b i a .  T o  a b l a t e  t h e  g a s t r o c n e m i u s  a n d  p l a n t a r i s ,  
t h e  l a t e r a l  a n d  m e d i a l  h e a d s  o f  t h e  m u s c l e  a r e  i s o l a t e d  w i t h  
c a r e f u l  b l u n t  e n d  d i s s e c t i o n .  T h e  d i s t a l  2 / 3  o f  t h e  g a s t r o c n e m i u s  
a n d  p l a n t a r i s  a r e  r e m o v e d  w i t h  c a r e  n o t  t o  d i s t u r b  t h e  v a s c u l a t u r e  
a n d  n e r v e s  a s s o c i a t e d  w i t h  t h e  s o l e u s .  T o  a b l a t e  t h e  t i b i a l i s  
a n t e r i o r  t h e  d i s t a l  t e n d o n  i s  c u t  a n d  t h e  m u s c l e  r e m o v e d  in  t o t o .  
T h e  f a s c i a  a n d  s k i n  a r e  t h e n  s u t u r e d  d i s t a l  t o  p r o x i m a l  w i t h  5 - 0  
s i l k .
Will multiple survival surgeries be performed? X WO 
______ YES
If yes, describe and justify:
3. a. Normally, it is not persûssible to use paralysing 
agents without general anesthetics. Will paralysing 
drugs be used?
X NO ______ YES. If yes, list:
Species Drug Dose/Kg Body Wt. Route Freq.
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b. How and by wh«m will tha laval of anasthasia be 
assessed and how often will the assessment be made?
L e v e l  o f  a n e s t h e s i a  w i l l  b e  a s s e s s e d  b y  r e f l e x  r e s p o n s e  t o  
t o e  p i n c h  a n d  t a i l  p i n c h .  P . I .  o r  CO P . I .  w i l l  m a k e  d e t e r m i n a t i o n  
p r i o r  t o  i n i t i a t i o n  o f  s u r g e r y .  I f  d u r i n g  t h e  s u r g i c a l  p r o c e d u r e  
t h e  a n i m a l  i s  a s s e s s e d  a s  b e i n g  " l i g h t l y "  a n e s t h e t i z e d ,  
s u p p l e m e n t a l  P e n t o b a r b i t a l  S o d i u m  ( 1 - 2  m g / l O O g  b o d y  w e i g h t )  w i l l  b e  
a d m i n i s t e r e d .
c. What criteria will be used to evaluate
pain/discomfort?
C r i t e r i a  f o r  a d e q u a t e  l e v e l  o f  a n e s t h e s i a  ( l a c k  o f  p a i n  o r  
d i s c o m f o r t )  w i l l  b e  t h e  a b s e n c e  o f  p i n c h  r e f l e x  i n  t o e s  o r  t a i l .
d. What methods will be used to prevent dehydration and 
hypothermia during surgery?
T i s s u e s  w i l l  b e  m o i s t e n e d  w i t h  p h y s i o l o g i c a l  s a l i n e  d u r i n g  
s u r g e r y  i f  n e c e s s a r y .  S u r g e r y  w i l l  b e  p e r f o r m e d  u n d e r  a  l a m p  t o  
r e d u c e  t h e  r i s k  o f  h y p o t h e r m i a .
e. For a non-survival study, what is the duration of 
surgery and study prior to the animal being euthanitired?
E l e c t r i c a l  s t i m u l a t i o n  p r o c e d u r e  ( s e e  1 7  f . )  w i l l  b e  n o n ­
s u r v i v a l .  D u r a t i o n  o f  t h i s  p r o c e d u r e  p r i o r  t o  e u t h a n i z a t i o n  w i l l  
b e  a p p r o x i m a t e l y  3 0  m i n  p e r  r a t .
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Post-Operative Care for Survival Studies:
a. Post-Anesthesia Recovery - Describe the observations 
that will ensure that the animals are stable and 
returning to a safe level of recovery from anesthesia and 
indicate who will be responsible for the observations :
P I  o r  C o - P I  w i l l  c h e c k  r a t s  p e r i o d i c a l l y  ( a p p r o x i m a t e l y  
e v e r y  1 5  m i n u t e s ) ,  w h i l e  i n  t h e i r  c a g e s  u n t i l ,  c o n s c i o u s n e s s  i s  
r e g a i n e d  a n d  l o c o m o t i o n  r e s u m e d .
b. Post-Surgical Recovery - Describe the frequency of 
examination and observation of the animal and management 
procedures for potential es^eriment-related diseases :
R a t s  w i l l  b e  o b s e r v e d  a t  l e a s t  t w i c e  d a i l y  a t  f e e d i n g  t i m e s .
c. What criteria will be used to evaluate post-operative 
pain, distress, or discomfort?
O b s e r v a t i o n  o f  P .  I . ,  C o  P .  I . ,  a t t e n d i n g  v e t e r i n a r i a n ,  o r  L A C F  
s t a f f  o f  p a i n ,  d i s t r e s s ,  o r  d i s c o m f o r t .
d. List post-operative medications which may be used 
(e.g., antibiotics or analgesics) . If the use of such 
agents would interfere with the project objectives, 
explain and document with objective data:
B u t o r p h a n o l  ( 0 . 1 - 0 . 5  m g / K g  b o d y  w e i g h t ) ,  b i d  ( e v e r y  1 2  h o u r s )  
b y  s u b c u t a n e o u s  i n j e c t i o n  a s  d e e m e d  n e c e s s a r y  b y  a t t e n d i n g  
v e t e r i n a r i a n .
e. Bow long will the animals be kept alive after the 
surgery?
4 t o  6  w e e k s  f o l l o w i n g  i n i t i a l  a b l a t i o n  s u r g e r y .
f . Describe any long-term care required post-surgically. 
If animals are chronically implanted or 
instrusiented, this section should be completed.
N o n e
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ANOVA Table: Animal Growth
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Source DF Sum of Squares Mean Square F Value Pr > F
GRP
SUV
SÜBJ
(a tp* 8 0 P
2
1
5
2
816.66666667
3117.36111111
6107.91666667
4206.22222222
408.33333333 0.77 0.4733
3117.36111111 5 .8 9  0.0228
1221.58333333 2.31 0.0747
2103.11111111 3 .9 7  0.0318
Error
Corrected Total
25
35
13242.58333333
27490.75000000
529.70333333
ANOVA Table: Muscle Size
Source
MOS
SOP
SRS
SDBJ
MOS*SOP
MDS*SBS
SDP*SRG
MDS»SDP*SRG
DF Anova SS Mean Square F Value Pr > F
169512.04166667 169512.04166667 8 .9 9  0.0037
8325.37500000 8325.37500000 0.44 0.5084
914160.66666667 914160.66666667 48 .48  0.0001
178610.12500000 16237.28409091 0.86 0.5810
16485.04166667 16485.04166667 0.87 0.3527
202768.16666667 202768.16666667 10 .75  0.0016
2860.16666667 2860.16666667 0.15 0.6980
21480.16666667 21480.16666667 1.14 0.2892
Error
Corrected Total
77
95
1451899.87500000
2966101.62500000
18855.84253247
ANOVA Table: Peak Force
Source DF Anova SS Mean Square F Value Pr > F
TIM 1 13090.94460000 13090.94460000 57 .35  0.0006
SDBJ(TIM) 5 1141.36810000 228.27362000 •
MUS 1 528.75093750 528.75093750 1.74 0.1920
SOP 1 7.72935000 7.72935000 0.03 0.8739
SRS 1 5168.24150417 5168.24150417 1 6 .9 6  0.0001
MOS*SOP 1 16.66666667 16.66666667 0.05 0.8158
MOS*TIM 1 463.40881667 463.40881667 1.52 0.2216
MOS*SRG 1 72.69720417 72.69720417 0.24 0.6267
SOP*TIM 1 76.43370417 76.43370417 0.25 0.6180
SOP*SRG 1 54.00000000 54.00000000 0.18 0.6751
TIM*SRG 1 27.34935000 27.34935000 0.09 0.7654
MOS*SOP*TIM 1 327.30320417 327.30320417 1.07 0.3036
MOS*SOP*SRG 1 0.61440000 0.61440000 0.00 0.9643
MOS*TIM*SRG 1 37.35015000 37.35015000 0.12 0.7273
SOP*TXM*SRG 1 105.21833750 106.21833750 0.35 0.5568
MOS*SOP*TIM*SRG 1 176.09583750 176.09583750 0.58 0.4497
MOS*SOP*SRG*SOB(TIM) 70 21328.194 58750 304.68849411
Corrected Total 95 42875.90294063
ANOVA Table: Percent Recovery of Force
Source DF Anova SS Mean Square F Value Pr > F
MOS 1 10830.02083333 10830.02083333 6 .1 5 0 .0181
SOP 1 1958.40750000 1958.40750000 1.11 0.2987
SSG 1 9009.12000000 9009.12000000 5 .1 2 0.0300
SOBJ 12648.35250000 2529.67050000 1.44 0.2353
MOS*SOP 1 434.40333333 434.40333333 0.25 0.6224
MOS*SRG 1 197.64083333 197.64083333 0.11 0.7395
SOP*SRG 1 457.56750000 457.56750000 0.26 0.6133
MOS*SOP*SRG 1 32.67000000 32.67000000 0.02 0.8924
Error 35 61592.77750000 1759.79364286
Corrected Total 47 97160.96000000
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ANOVA Table: Size Corrected Peak Force
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Source OF Anova SS Mean Square F Value Pr > F
TZK 1 2587.63050104 2587.63050104 75.00 0.0003
SDBJ(TIM) 5 172.50071771 34 .50014354 • •
MDS 1 2.10930104 2.10930104 0.04 0.8372
SUP 1 11.47475104 11.47475104 0.23 0.6320
SRS 1 469.80225938 469.80225938 9.47 0.0030
MOS’SDP 1 63.91238437 63.91238437 1.29 0.2602
MDS'TIM 1 143.39925938 143.39925938 2.89 0.0935
MDS*SRS 1 588.40655104 588.40655104 11 .86 0.0010
SOP*TIM 20.45183438 20.45183438 0.41 0.5229
SDP*SRG 1 2.02710937 2.02710937 0.04 0.8404
T3X*SR8 1 265.83398438 265.83398438 5 .3 6 0.0236
MDS*SOP*TIM 1 70.57225104 70.57225104 1.42 0.2370
MUS*SUP»SRG 1 99.98042604 99.98042604 2.02 0.1601
MDS*TIM»SRG 1 2.4 6720937 2.46720937 0.05 0.8242
SOP»TIM*SRG 1 19.41300937 19.41300937 0.39 0.5336
MOS*SDP*TIM*SHG 1 36.14987604 36.14987604 0.73 0.3962
MDS*SOP*SRG*SOB(TIM) 70 3472.21008125 49.60300116
Corrected total 95 8193.95114896
ANOVA Table: Total Tensions First 30 Seconds
Source DF Anova SS Mean Square F Value Pr > F
TIK 1 8273008.10962604 8273008.10962604 118.91 0.0001
SDBJ (TIM) 5 347866.22206771 69573.24441354 • -
MDS 1 283903.84137606 283903.84137606 1.76 0.1885
SDP 1 0.08942606 0.08942606 0.00 0.9994
SRG 1 3800330.98255105 3800330.98255105 23 .60 0.0001
MDS*SOP 1 8364.72012603 8364.72012603 0.05 0.8204
MDS*TIM 1 14779.56585938 14779.56585938 0.09 0.7628
MDS*SRG 1 85945.20008437 85945.20008437 0.53 0.4675
SDP*TIM 1 5325.40937605 5325.40937605 0.03 0.8562
SDP*SRG 1 51674.28805103 51674.28805103 0.32 0.5729
TIM*SRG 1 367226.95312606 367226.95312606 2.28 0.1355
MDS*SDP*TIM 1 106323.60960937 106323.60960937 0.66 0.4192
MDS*SOP*SRG 1 55031.83625105 55031.83625105 0.34 0.5607
MDS*TIM*SRG 1 14153.54085936 14153.54085936 0.09 0.7677
SDP*TIM*SRG 1 4996.67612602 4996.67612602 0.03 0.8607
MDS*SDP*TIM*SRG 1 453.92252604 453.92252604 0.00 0.9578
MDS*SDP*SRG*SOB (TIM) 70 11271372.13573950 161019.60193914
Corrected Total 95 24874304.08989580
ANOVA Table: Percent Recovery of Tension of First 30 Seconds
Source DF Anova SS Mean Square F Value Pr > F
MDS 1 3111.32505208 3111.32505208 4 .9 6 0 .0325
SDP 1 718.96860208 718.96860208 1.15 0.2918
SRG 1 884.16916875 884.16916875 1.41 0.2432
SDBJ 2507.27016042 501.45403208 0.80 0.5579
MDS*SDP 1 425.48475208 425.48475208 0.68 0.4158
MDS*SRG 1 80.16085208 80.16085208 0.13 0.7229
SDP*SRG 1 2363.63435208 2363.63435208 3.77 0.0604
MDS*SDP*SRG 1 525.29716875 525.29716875 0.84 0.3665
Error
Corrected Total
35
47
21963.75998958
32580.07009792
627.53599970
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ANOVA Table: Total Tension Second 30 Seconds
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Source DF Anova SS Mean Square F Value Pr > F
TIM 1 1468855.85992605 1468855.85992605 76.92 0.0003
SOBJ(TIM) 5 95484.79216771 19096.95843354 - •
MOS 1 113286.98745938 113286.98745938 2.27 0.1362
SOP 1 26545.13877605 26545.13877605 0.53 0.4680
SRC 1 1115158.70377605 1115158.70377605 22.37 0.0001
MOS'SOP 1 37024.93537603 37024.93537603 0.74 0.3918
MDS'TIM 1 28240.21917604 28240.21917604 0.57 0.4542
MOS’SRG 49422.90420937 49422.90420937 0.99 0.3228
SOP*TIM 1 10585.47005104 10585.47005104 0.21 0.64 64
SOP*SRG 1 99733.15690103 99733.15690103 2.00 0.1617
TIM*SRG 1 37257.82200937 37257.82200937 0.75 0.3903
MOS*SOP*TIM 1 536.61855104 536.61855104 0.01 0.9177
MDS*SOP*SRG 1 9418.66450105 9418.66450105 0.19 0.6652
MOS»TIM*SRG 1 76824.88992605 76824.88992605 1.54 0.2186
SOP*TIM»SRG 1 2236.194 67605 2236.19467605 0.04 0.8329
MOS*SOP*TIM*SRG 1 1844.76967604 1844.76967604 0.04 0.8480
MOS*SOP*SRG*SOB(TIM) 70 3489847.79529791 49854.96850426
Corrected Total 95 13606186.85022390
ANOVA Table: Time to One-Half Peak Force
Source DF Anova SS Mean Square F Value Pr > F
TIM 1 661.55250104 661.55250104 19.34 0.0070
SDBJ(TIM) 5 171.05426771 34.21085354 • -
MDS 1 1233.59850938 1233.59850938 9.46 0.0030
SOP 1 1054.89930104 1054.89930104 8 .09 0.0058
SRG 1 1497.76100104 1497.76100104 11.48 0.0012
MOS*SDP 1 771.40350938 771.40350938 5 .91 0.0176
MOS’TIM 1 45.52637604 45.52637604 0.35 0.5566
MOS'SRG 1 142.52063437 142.52063437 1.09 0.2995
SOP*TIM 1 1.96940104 1.96940104 0.02 0.9026
SOP*SRG 1 1114.59325104 1114.59325104 8.54 0.0047
TIM*SRG 1 78.13845937 78.13845937 0.60 0.4416
MDS*SOP*TIM 1 2.83937604 2.83937604 0.02 0.8831
MDS*SDP*SRG 1 313.09538437 313.09538437 2.40 0.1259
MOS*TIM*SRG 1 3.79612604 3.79612604 0.03 0.8650
SDP*TIM*SRG 1 11.57175938 11.57175938 0.09 0.7667
MDS*SDP*TIM*SRG 1 99.28767604 99.28767604 0.76 0.3860
MDS*SOP*SRG*SOB(TIM) 70 9132.72512292 130.46750176
Corrected Total 95 17825.59100000
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EDL Stim Time (s) Force of contraction (g)
R a(# Group 0 10 20 30 40 50 60 70 80 90 100 110 120 130 140 150 160 170 180
19 Con-C
22 27.01 11.74 5.84 4.02 2.59 2.04 1.22 0.97 0.70 0.68 0.66 0.58 0.52 0.53 0.36 0.48 0.40 0.47 0.49
24 51.14 25.64 14.26 6.91 3.43 2.80 2.89 2.01 1.75 1.44 1.17 0.92 0.84 0.68 0.67 0.76 0.80 0.63 0.52
27 40.53 24.25 10.87 5.47 4.29 4.22 3.35 2.73 2.38 2.11 1.53 1.27 1.07 0.91 0.85 0.78 0.65 0.76 0.70
32 50.25 30.90 19.92 13.62 7.39 5.00 3.82 3.10 2.83 2.60 2.29 2.08 1.96 1.89 2.03 1.77 1.62 1.68 1.73
36 36.75 20.21 14.20 9.71 6.87 6.79 4.52 3.58 3.00 2.50 1.74 1.63 1.50 1.32 1.20 1.22 1.24 1.06 1.02
Mean 41.14 22.55 13.02 7.95 4.91 4.17 3.16 2.48 2.13 1.87 1.48 1.30 1.18 1.07 1.02 1.00 0.94 0.92 0.89
StErr 4.48 3.20 2.31 1.70 0.95 0.84 0.55 0.46 0.42 0.36 0.27 0.26 0.25 0.25 0.29 0.23 0.22 0.21 0.23
10 C o n C r 37.09 28.11 20.34 14.01 10.55 8.17 6.40 5.91 5.54 4.30 3.95 3.52 2.71 4.13 6.47 7.93 4.58 4.89 4.35
16 1.74 1.14 0.57 0.27 0.17 0.16 0.18 0.08 0.00
21 49.06 31.68 25.57 19.75 15.67 12.24 9.55 7.40 6.32 7.08 6.47 6.03 5.68 5.29 4.96 4.81 4.75 4.74 4.28
29 64.87 27.63 17.34 12.35 10.68 6.12 6.28 4.12 4.24 4.55 3.47 4.49 3.11 2.77 2.07 2.07 1.82 1.61 1.61
30 16.88 12.02 9.19 5.46 3.00 1.78 1.68 1.15 0.82 0.78 0.54 0.00
33 46.39 20.30 4.51 1.95 1.82 3.12 2.84 1.71 1.16 1.14 0.81 0.59 0.00
Mean 36.01 20.15 12.92 8.97 6.98 5.27 4.49 3.40 3.01 3.57 3.05 2.93 2.88 4.06 4.50 4.94 3.72 3.75 3.41
SlErr 9.40 4.76 3.97 3.11 2.52 1.83 1.43 1.18 1.10 1.17 1.10 1.15 1.16 0.73 1.29 1.69 0.95 1.07 0.90
4 H y p C 58.72 58.54 49.03 32.97 19.44 12.59 9.14 7.28 6.32 5.36 4.40 4.03 3.52 3.72 2.62 2.40 2.36 1.90 1.78
11 36.57 32.58 33.78 21.35 15.55 13.14 11.50 11.09 9.62 9.71 9.50 9.36 7.44 8.72 8.31 7.09 6.59 7.01 6.87
12 47.98 29.83 26.80 21.60 14.69 10.98 9.05 8.55 6.50 5.87 4.62 5.03 4.71 4.23 4.05 4.06 4.00 3.83 3.81
15 57.52 34.28 20.82 20.78 15.66 10.02 6.78 5.06 4.24 3.78 3.32 2.84 2.59 2.89 3.12 3.22 2.93 2.58 2.52
20 57.67 44.15 36.73 26.66 19.40 14.43 11.55 9.55 8.43 8.18 7.72 7.25 7.15 6.88 6.72 6.51 6.41 6.41 6.26
35 66.63 59.34 58.11 56.31 39.70 28.95 22.84 14.11 14.71 12.15 12.26 10.59 9.74 8.51 8.21 8.84 7.52 8.78 8.91
Mean 54.18 43.12 37.55 29.95 20.74 15.02 11.81 9.27 8.30 7.51 6.97 6.52 5.86 5.83 5.51 5.35 4.97 5.09 5.03
StErr 4.27 5.38 5.67 5.61 3.88 2.86 2.32 1.28 1.49 1.27 1.42 1.25 1.11 1.04 1.05 1.02 0.88 1.11 1.13
7 HypX:r 30.40 16.72 12.05 9.07 5.87 4.59 3.70 2.97 2.80 2.57 2.57 2.55 2.32 2.28 2.18 2.18 2.04 1.96 2.02
8 22.33 10.67 7.43 4.68 2.94 2.28 1.98 1.88 1.57 1.41 1.37 1.12 1.03 0.98 0.93 1.02 0.92 1.35 1.49
9 68.46 67.87 57.48 41.48 31.47 26.72 20.46 16.87 17.87 16.81 15.25 15.11 14.20 13.18 12.75 12.55 12.36 13.44 14.00
13 57.29 50.60 40.08 33.84 27.18 19.62 16.21 13.54 12.57 11.59 10.96 10.46 10.01 9.69 9.82 9.92 9.83 9.76 10.12
23 56.95 57.35 53.59 39.32 27.03 17.33 13.48 11.96 10.40 9.22 7.93 7.47 7.07 6,40 6.47 4.67 5.02 5.47 5.91
26 71.53 49.84 34.31 21.44 11.53 7.65 6.21 5.41 4.33 3.32 3.05 2.82 3.37 3.98 2.95 4.23 3.45 3.21 2.47
Mean 51.16 42.18 34.16 24.97 17.67 13.03 10.34 8.77 8.26 7.49 6.86 6.59 6.33 6.09 5.85 5.76 5.60 5.87 6.00
StErr 8.26 9.42 8.48 6.41 5.04 3.94 3.04 2.52 2.62 2.48 2.25 2.23 2.07 1.90 1.91 1.85 1.85 1.96 2.08
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EDL Rccov Time (s) Force o f  contractions (g)
R a t#  Group 0 10 20 30 40 50 60 70 80 90 100 110 120
19 Con-C
22 4.76 1.35 0.83 0.42 0.33 0.27 0.19 0.16 0.17 0.18 0.17 0.18 0.26
24 6.70 2.47 1.42 0.72 0.38 0.17 0.13 0.00
27 3.81 1.75 1.05 0.88 0.71 0.39 0.27 0.26 0.21 0.21 0.26 0.16 0.11
32 8.41 3.06 2.62 1.76 1.27 1.18 1.03 0.92 0.81 0.77 0.76 0.78 0.75
36 7.32 2.44 2.06 1.56 1.29 1.01 0.99 1.04 1.00 0.93 0.91 0.88 0.85
Mean 6.20 2.21 1.60 1.07 0.80 0.60 0.52 0.48 0.55 0.52 0.53 0.50 0.49
StErr 0.84 0.30 0.33 0.25 0.21 0.21 0.20 0.21 0.21 0.19 0.18 0.19 0.18
10 Con-Cr 17.78 6.55 5.74 3.67 3.38 4.15 2.59 2.98 2.75 2.13 2.22 2.15 2.03
16 1.63 0.86 0.32 0.48 2.85 4.69 4.53 0.35 1.65 1.71 1.61 4.55 4.10
21 25.87 14.48 10.74 8.34 7.00 6.16 5.22 5.26 4.78 4.52 4.40 4.92 5.02
29 11.50 2.99 2.36 1.67 1.27 0.93 0.84 0.74 0.76 0.78 0.70 0.67 0.59
30 0.65 0.84 0.22 0.20 0.00 0.00 0.00 0.24 0.08 0.00 2.42 1.44 0.66
33 7.45 3.92 2.91 1.99 1.35 0.99 0.85 0.72 0.65 0.63 0.58 0.54 0.53
Mean 10.81 4.94 3.72 2.73 2.64 2.82 2.34 1.72 1.78 1.63 1.99 2.38 2.16
StErr 3.98 2.10 1.63 1.23 1.00 1.02 0.88 0.82 0.71 0.66 0.57 0.78 0.80
4 H yp-c 15.86 2.18 1.83 1.93 1.83 1.58 1.39 1.24 1.20 0.95 0.81 0.73 0.72
11 24.80 14.41 8.20 5.94 4.19 3.91 3.68 3.56 3.66 3.72 3.73 3.58 3.84
12 17.48 6.53 4.89 3.89 2.77 3.42 3.55 3.69 3.49 4.35 4.26 4.28 3.89
IS 22.11 12.83 12.18 11.66 16.02 11.50 9.20 6.60 6.57 7.61 9.59 7.59 6.14
20 25.84 15.93 13.50 11.55 9.67 7.74 6.81 6.17 5.60 5.36 5.12 4.72 4.89
35 29.90 18.28 15.36 13.56 12.25 11.31 10.23 9.78 9.37 9.50 8.75 9.33 9.15
Mean 22.67 11.69 9.33 8.09 7.79 6.58 5.81 5.17 4.98 5.25 5.38 5.04 4.77
StErr 2.16 2.50 2.15 1.96 2.34 1.73 1.43 1.22 1.16 1.23 1.34 1.24 t 14
7 Hyp-Cr 8.55 3.80 3.04 2.63 2.07 1.61 1.36 1.28 1.19 1.13 1.10 1.08 1.04
8 6.90 1.75 1.01 0.80 0.66 0.47 0.41 0.41 0.36 0.34 0.32 0.34 0.32
9 50.35 31.10 22.94 18.75 15.21 13.81 13.31 12.76 12.09 11.76 11.42 11.93 11.95
13 65.87 36.79 27.27 21.46 17.09 14.94 13.79 13.07 12.46 12.09 11.63 11.19 11.09
23 40.77 18.38 12.45 11.17 8.36 6.83 5.90 5.09 4.73 4.32 4.01 3.75 3.50
26 18.41 5.27 2.92 2.05 1.74 1.68 1.82 1.61 0.92 1.72 1.66 0.93 1.16
Mean 31.81 16.18 11.61 9.48 7.52 6.56 6.10 5.70 5.29 5.23 5.02 4.87 4.84
StErr 9.87 6.14 4.60 3.70 2.95 2.63 2.48 2.37 2.30 2.19 2.12 2.17 2.16
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Sol Stim Time (s) Force o f  contractions (g)
R a t#  Group 0 10 20 30 40 50 60 70 80 90 100 110 120 130 140 150 160 170 180
19 Con-C
22 46.71 32.88 28.07 21.40 15.31 11.11 8.82 6.69 5.39 4.45 3.75 3.14 2.69 2.42 2.04 1.94 1.96 1.80 1.71
24 54.03 50.69 43.27 38.22 24.07 17.53 12.76 8.70 7.00 4.33 4.26 4.93 4.41 4.69 7.19 7.55 3.99 3.37 2.86
27 31.40 21.14 19.98 15.17 13.16 9.31 5.95 4.34 3.61 2.79 3.21 2.61 1.87 1.63 1.04 1.20 1.09 0.84 0.70
32 39.20 3.03 2.23 1.85 1.48 1.21 0.90 0.92 0.78 0.55 0.52 0.41 0.53 0.62 0.30 1.97 0.66 0.89 0.83
36 36.75 31.68 25.91 18.56 18.56 9.82 8.09 6.14 4.84 4.88 4.29 3.73 2.99 2.68 2.60 1.95 1.96 1.83 1.52
Mean 41.62 27.88 23.89 19.04 14.52 9.80 7.30 5.36 4.32 3.40 3.21 2.96 2.50 2.41 2.63 2.92 1.93 1.75 1.52
SlErr 3.96 7.82 6.64 5.85 3.74 2.60 1.94 1.31 1.04 0.80 0.70 0.75 0.64 0.67 1.21 1.17 0.57 0.46 0.39
10 Con-Cr 0.91 0.62 0.22 0.40 0.55 0.59 0.53 0.54 0.62 0.65 0.60 0.58 0.68 0.63 0.64 0.66 0.69 0.75 0.69
16 22.69 13.32 7.70 4.04 3.03 2.37 1.90 1.44 0.96 0.86 0.66 0.53 0.49 0.49 0.44 0.39 0.42 0.44 0.44
21 62.53 49.08 48.23 35.35 22.91 15.13 12.15 10.55 9.19 7.77 6.47 5.81 5.23 4.92 4.54 4.29 4.10 3.90 3.63
29 53.99 40.97 33.44 23.27 15.71 11.34 9.15 7.54 5.43 4.39 3.53 2.93 2.61 2.38 2.25 2.06 2.05 1.92 1.89
30 44.22 36.19 34.72 30.88 25.78 20.48 13.29 9.20 7.10 5.21 3.68 3.10 2.58 2.18 1.97 1.68 1.56 1.45 1.38
33 38.31 30.61 25.14 21.13 14.99 10.02 7.54 6.32 5.40 4.52 3.97 3.61 3.30 3.62 3.40 3.53 3.21 3.30 2.54
Mean 37.11 28.47 24.91 19.18 13.83 9.99 7.43 5.93 4.78 3.90 3.15 2.76 2.48 2.37 2.21 2.10 2.01 1.96 1.76
StErr 9.13 7.42 7.35 5.78 4.18 3.08 2.14 1.67 1.38 1.11 0.91 0.81 0.72 0.70 0.65 0.63 0.59 0.57 0.49
2 H y p C 63.98 59.71 60.10 60.42 37.24 29.07 24.87 21.63 21.15 20.27 22.24 22.98 24.16 25.54 26.20 28.62 31.20 30.83 32.01
3 71.74 65.38 68.32 45.77 26.15 18.57 13.51 10.68 9.60 9.00 8.29 8.87 7.32 6.99 6.81 6,04 5.52 5.65 5.82
5 45.72 35.07 29.95 24.48 18.60 15.16 13.20 12.13 10.73 9.71 8.91 8.21 7.42 7.63 7.96 7.83 8.57 5.49 4.90
6 1.79 2.65 1.02 1.97 2.19 2.37 2.29 2.61 1.55 1.29 1.09 0.93 0.86 0.55 0.56 0.73 0.72 0.75 0.58
18 44.54 35.61 34.68 34.74 28.36 22.78 20.05 18.67 18.03 17.53 17.89 14.27 13.51 12.80 12.32 12.51 12.22 12.48 12.95
31 63.71 57.75 41.17 21.82 15.96 13.69 12.20 10.54 8.85 7.67 6.67 5.85 5.45 4.87 5.35 4.78 3.62 3.57 3.53
Mean 45.50 39.29 35.03 25.76 18.25 14.51 12.25 10.93 9.75 9.04 8.57 7.63 6.91 6.57 6.60 6.38 6.13 5.59 5.56
StErr 10.35 9.56 9.75 8.30 4.93 3.70 3.14 2.75 2.86 2.83 3.17 3.11 3.32 3.56 3.62 4.03 4.48 4.49 4.72
1 H y p C r 63.30 32.44 16.07 10.84 8.94 7.61 6.32 5.75 5.02 4.37 3.72 3.29 3.08 2.60 2.42 2.32 1.97 1.86 1.73
14 52.49 50.68 30.20 16.87 10.31 7.10 4.78 3.72 2.95 2.36 2.25 2.14 1.94 1,98 2.04 2.36 2.91 3.76 4.24
17 28.17 21.17 17.33 11.77 7.96 5.40 4.50 3.17 3.12 2.99 2.84 2.55 2.14 1.95 2.11 2.11 2.81 3.42 3.68
25 66.19 45.17 40.68 32.64 24.46 18.83 14.20 12.05 10.61 9.10 8.50 7.32 7.68 7.23 6.66 6.11 5.85 5.76 5.89
28 58.11 56.15 43.99 31.04 19.56 12.48 9.43 9.01 9.85 10.34 9.53 7.91 7.47 6.90 6.54 6.01 5.59 5.70 5.67
34 69.69 55.49 43.19 31.25 23.53 21.02 18.80 17.51 16.76 16.07 15.41 16.45 14.12 13.40 12.42 11.87 12.56 6.99 4.40
Mean 56.33 43.52 31.91 22.40 15.79 12.07 9.67 8.54 8.05 7.54 7.04 6.61 6.07 5.68 5.37 5.13 5.28 4.58 4.27
StErr 6.15 5.71 5.22 4.22 3.10 2.68 2.35 2.26 2.20 2.17 2.08 2.21 1.92 1.83 1.66 1.55 1.59 0.77 0.62
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Sol Recov Timo (s) Froce o f  contractions (g)
R a t#  Group 0 10 20 30 40 50 60 70 80 90 100 110 120
19 Con-C
22 28.01 14.12 5.26 2.88 2.00 1.63 1.63 1.41 1.14 1.07 0.88 1.01 1.01
24 36.43 22.69 13.32 11.43 3.98 2.77 2.09 2.41 1.59 1.56 2.00 2.01 1.78
27 12.13 2.39 1.16 0.69 0.29 0.25 0.28 0.17 0.25 0.20 0.23 0.10 0.17
32 2.20 3.09 2.07 1.27 0.93 0.75 0.76 0.82 0.85 0.95 0.78 0.72 0.80
36 20.90 8.85 5.60 3.53 2.60 2.04 1.51 1.34 1.26 1.12 1.01 0.98 0.96
Mean 19.93 10.23 5.48 3.96 1.96 1.49 1.25 1.23 1.02 0.98 0.98 0.96 0.94
StErr 5.97 3.77 2.14 1.94 0.65 0.45 0.32 0.37 0.23 0.22 0.29 0.31 0.26
10 C o n C r 0.76 0.50 0.69 0.70 0.76 0.59 0.63 0.62 0.62 0.59 0.68 0.67 0.63
16 10.06 5.89 3.51 2.31 1.96 2.52 1.74 1.81 1.83 1.57 1.03 0.84 0.55
21 43.01 13.95 7.18 5.18 4.94 4.31 5.20 4.92 4.75 4.81 5.22 5.06 5.06
29 21.76 11.31 5.02 3.38 2.43 1.87 1.59 1.44 1.39 1.40 1.37 1.36 1.36
30 29.64 12.78 6.46 2.61 1.76 1.44 1.24 1.19 1.15 1.07 1.08 1.07 1.03
33 22.16 19.14 12.62 8.79 6.35 4.90 4.22 3.80 3.34 3.12 2.85 2.62 2.69
Mean 21.23 10.60 5.91 3.83 3.03 2.61 2.44 2.30 2.18 2.09 2.04 1.94 1.89
StErr 6.03 2.67 1.64 1.16 0.87 0.69 0.75 0.69 0.64 0.65 0.71 0.69 0.71
2 Hyp-C 56.87 55.38 46.68 38.52 35.39 35.76 36.43 36.36 36.36 36.46 36.62 36.47 36.10
3 72.80 25.44 6.72 3.13 3.51 4.68 5.18 4.88 5.21 5.41 4.70 4.42 5.33
5 24.49 16.50 11.50 8.62 7.56 7.43 7.07 6.78 6.69 6.53 6.21 6.01 6.01
6 2.69 1.03 2.06 2.62 2.26 1.88 1.41 1.38 1.74 1.48 1.13 1.20 1.22
18 31.51 24.85 17.94 15.61 13.91 13.83 14.45 15.58 16.97 17.84 18.46 18.62 18.45
31 28.60 4.65 3.01 2.36 2.07 1.88 1.87 1.81 1.57 1.51 1.46 1.47 1.46
Mean 32.02 14.49 8.25 6.47 5.86 5.94 6.00 6.09 6.44 6.55 6.39 6.34 6.49
StErr 10.18 7.96 6.84 5.74 5.25 5.29 5.43 5.47 5.49 5.55 5.66 5.66 5.56
1 H ypC r 16.35 1.43 0.93 0.74 0.66 0.59 0.55 0.49 0.45 0.46 0.44 0.34 0.34
14 64.04 36.48 16.84 12.56 11.18 10.18 9.06 8.34 7.85 7.57 7.48 7.85 7.48
17 11.88 3.72 3.22 2.09 1.37 1.03 1.37 2.41 3.08 3.07 2.84 2.45 2.26
25 27.14 13.40 13.25 7.56 6.40 5.87 5.37 5.30 4.74 4.49 3.79 3.85 3.52
28 25.39 13.07 7.59 6.06 5.72 5.62 5.49 5.27 5.50 5.70 5.58 5.61 5.49
34 38.28 24.46 18.75 15.45 13.82 13.11 12.61 12.28 12.03 12.05 12.14 12.22 12.01
Mean 30.51 15.43 10.10 7.41 6.53 6.07 5.74 5.68 5.61 5.56 5.38 5.39 5.18
StErr 7.68 5.38 2.99 2.35 2.13 2.02 1.87 1.72 1.63 1.63 1.67 1.72 1.70
004^
REFERENCES
Balsom, P.D., Harridge, S.D.R., Soderlund, K., Sjodin, B. & Ekblom, B. (1993) 
Creatine supplementation per se does not enhance endurance exercise performance. Acta 
Physiol Scand, 149:521-523.
Balsom, PJD., Soderhmd, K. &  Ekblom, B. (1994) Creatine in humans with 
special reference to creatine supplementation. Sports MediciM, 18:268-280.
Balsom, P.D., Soderlund, K., Sjodin, B. & Ekblom, B. (1995) Skeletal muscle 
metabolism during short duration high intensity exercise: influence of creatine 
supplementation. Acta Physiol Scand, 154:303-310.
Barmett, C., Hinds, M , & Jenkins, D.G. (1996) Effects o f oral creatine 
supplementation on multiple sprint cycle performance. The Australian Journal o f Science 
and Medicine in Sport, 28:35-39.
Bessman, S.P. & Carpenter, C.L. (1985) The creatine-creatine phosphate energy 
shuttle. Annual Reviews in Biochemistry, 54:831-62.
Birch, R-, Noble, D. & Greenhafi^ P.L. (1994) The influence of dietary creatine 
supplementation on performance during repeated bouts o f  maximal isokinetic cycling in 
man. European Journal o f Applied Physiology, 69:268-270.
Brannon, T.A., Adams, G.R., ConnifiF, C.L. & Baldwin, K.M. (1997) Effects o f 
creatine loading and training on running performance and biochemical properties o f  rat 
skeletal muscle. Medicine and Science in Sports and Exercise 29:489-495.
85
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
86
Burke, L.M., Pyne, D.B. & Telford, R.D. (1996) Effects o f  oral creatine 
supplementation on single-effort sprint performance in elite swimmers. International 
Journal o f Sports Nutrition, 6:222-233.
Cain, D.F. & Davies, R.E. (1962) Biochemistry and Biophysiology Research 
Communications, 8: 361-366.
Casey, A., Constantin-Teodosiu, D., Howell, S., Hukman, E. & GreenhaflF p.L. 
(1996) Creatine ingestion favorably affects performance and muscle metabolism during 
maximal exercise in humans. American Journal o f  Physfology, 271 ;E31-E37.
Cooke, W.H. & Barnes, W.S. (1997) The influence o f recovery duration on high 
intensity exercise performance after oral creatine supplementation. Canadian Journal o f 
y^plied Physiology, 22:454-467.
Cooke, W.H., Grandjean, P.W. & Barnes, W.S. (1995) Effect of oral creatine 
supplementation on power output and fatigue during bicycle ergometrv. Journal of 
Applied Physiology, 78:670-673.
Delanghe, J., De Slypere, J., De Buyzere, M-, Robbrecht, J., Wieme, R. & 
Vermeulen, A. (1989) Normal reference values for creatine, creatinine and carnitine are 
lower in vegetarians. Clinical Chemistry, 35:1802-1803.
Earnest, CJ*., Snell, P.O., Rodriguez, R , Almada, A.L. & Mitchell, T.L. (1995) 
The effect o f  creatine monohvdrate ingestion on anaerobic power indices, muscular 
strength and body composition. Acta Physiol Scand, 153:207-209.
Febbraio, M.A., Flanagan, T.R , Snow, R J., Zhao, S. & Carey, M.F. (1995)
Effect o f creatine supplementation on intramuscular TCr. metabolism and performance 
during intermittent- supramaximal exercise in humans, Acta Physiol Scand, 155:387- 
395.
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
87
Fiske, C.H. & Subbarow, Y. (1929) Science, 70: 381-83
Fitch, C D. & Chevli, R. (1980) Inhibition of creatine and phosphocreatine 
accumulation in skeletal muscle and heart. Metabolism, 29:686-90.
Fitch, C D., Chevli, R., Petrofeky, J.S. & Kopp, S.J. (1978) Sustained isometric 
contraction of skeletal muscle depleted o f  phosphocreatine. Life Sciences, 23:1285-92.
Fitch, C D., Jellinek, M., Fitts, R.H., Baldwin, K.M. & HoUoszy, J.O. (1975) 
Phosphorvlated (3-gnanidinopmpinnate as a substitute for phosphocreatine in rat muscle. 
American Journal o f  Physiology, 228:1123-25.
Fitts, R.H. (1994) Cellular mechanisms o f muscle fatigue. Physiological 
Reviews, 74:49-94.
Green, AX., Simpson, E.J., Littlewood, J.J., Macdonald, LA. &  Greenhaff, P.L. 
(1996) Carbohydrate ingestion augments creatine retention during creatine feeding in 
humans. Acta Physiol Scand, 158:195-202.
Greenhaffi P.L. (1995) Creatine and its application as an ergogenic aid. 
International Journal o f  Sport Nutrition, 5:S100-S110.
Greenhaff P.L., Bodin, K., Harris, R.C., Hukman, E., Jones, D.A., McIntyre,
D.B., Soderlund, K. & Turner, D.L. (1993) The influence o f oral creatine 
supplementation on muscle plwspbocreatine resvnthesis following intense contraction in 
man. Journal o f Physiology, 467:75P.
Greenhaff P.L., Bodin, K., Soderlund, K. & Hukman, E. (1994) Effect o f oral 
creatine supplementation on skeletal muscle phosphocreatine resvnthesis. American 
Journal of Physiology, 266:E725-E730.
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
88
Greenhaff P.L., Casey, A., Short, A.H., Harris, R., Soderlund, K. & Hultman, E. 
(1993) Influence o f oral creatine supplementation o f  muscle torque during repeated bouts 
o f  maximal voluntary exercise in man. Clinical Science, 84:565-571.
Grindstaff P.D., Kreider, R., Bishop, R., Wilson, M., Wood, L., Alexander, C. & 
Almada, A. (1997) Effects o f  creatine supplementation on repetitive sprint performance 
and body composition in competitive swimmers. International Journal o f Sports 
Nutrition, 7:330-346.
Haff G.G. & Potteiger, J.A. (1997) Creatine supplementation for the 
strength/power athlete. Strength and Conditioning, Dec: 72-74.
Harris, R C ., Edwards, RH .T., Hultman, E_, Nordesjo, L.O., Nylind, B. & Sahlin, 
K. (1976) The time course o f phosphorvlcreatine resvnthesis o f the quadriceps muscle in 
man. Pflugers Archives, 367:137-142.
Harris, R C ., Hultman, E. & Nordesjo, L.O. (1974) Glycogen, glycolytic 
intermediates and high-energy phosphates determined in biopsy samples o f musculus 
quadriceps femoris o f man at rest. Methods and variance o f  values. Scandinavian 
Journal o f Clinical Laboratory Investigations, 33:109-120.
Harris, R C ., Soderlund, K. & Hultman, E. (1992) Elevation o f creatine in resting 
and exercised muscle o f  normal subiects bv creatine supplementation. Clinical Science, 
83:367-374.
Harris, RC., Viru, M., Greenhaff PX. & Hukman, E. (1993) The effect o f oral 
creatine supplementation on running performance during maximal short term exercise in 
man. Journal o f Physiology, 467:74P.
Hill, D.K. (1960) Journal o f  Physiology, 153: 433-446.
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
89
Hirvonen, J., Rehunen, S., Rusko, H. & Harkoneo, M. (1987) Breakdown of 
high-energy phosphate compounds and lactate accumulation during short supramaximal 
exercise. European Journal o f  Physiology, 56:253-259.
Hukman, E., Bergstrom, J & McLennan Anderson, N. (1967) Breakdown and 
resvnthesis o f  phosphorvlcreatine and adenosine triphosphate in connection with 
muscular work in man. Scandinavian Journal o f  Clinical Laboratory Investigations, 
19:56-66.
Hultman, E., Greenhaff P.L., Ren, J. & Soderlund, K. (1990) Energy metabolism 
and fatigue during intense muscle contraction. Biochemical Society Transactions, 
19:347-353.
Hultman, E. Soderlund, K. Timmons, J.A., Cederblad, G. & Greenhaff P.L. 
(1996) Muscle creatine loading in men. Journal o f Applied Physiology, 81:232-237.
Jacobs, I., Bleue, S. & Goodman, J. (1997) Creatine ingestion increases 
anaerobic capacity and maximum accumulated oxygen defick. Canadian Journal of 
Physiology, 22:231-243.
Jacobsen, F.K., Christensen, C.K., Mogensen, C.E., Andreasen, P. & Heilskov, 
N.S.C. (1979) Pronounced increase in serum creatinine concentration after eating cooked 
meat. British Medical Journal, April 21:1049-1050.
Juhn, M.S. (1999) Oral creatine supplementation. Separating fact from hvpe. The 
Physician and Sportsmedicine, 27(5): 47-56.
Kandarian, S.C. &  Whke, T.P. (1990) Mechanical deficit persists during long­
term muscle hypertrophy. Journal o f Applied Physiology, 69:861-867.
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
90
Kandarian, S.C., Young, J.C. & Gomez, E.E. (1992) Adaptation in synergistic 
muscles to soleus and plantaris muscle removal in the rat hindlimb. Life Sciences, 
51:1691-1698.
Krieder, R.B. (1995) The effect o f creatine loading on muscular strength and 
body composition. Strength and Conditioning, Oct:72-73.
Krieder, R.B., Ferreira, M., Wilson, M., Grindstafif, P., Plisk, S., Reinardy, J., 
Gantier, E, & Almada, A.L. (1998) Effects o f  creatine supplementation on body 
composition, strength, and sprint performance. Medicine & Science in Sports &
Exercise, 30:73-82.
Lipmann, F. & M eyerhof O. (1930) Biochemistry, 227: 84-109.
McNaughton, L.R., Dalton, B. & Tarr, J. (1998) The effects o f creatine 
supplementation on high-mtensitv exercise performance in elite per&rmers. European 
Journal of Applied Physiology, 78:236-240.
MeryerhoC O. & Lohmann, K. (1932) Biochemistry, 252: 431-461.
Mommaerts, W.F.H.M. (1954) Nature, 174: 1083.
Mujika, I., Chatard, J., Lacoste, L., Barale, F. & Geyssant, A. (1996) Creatine 
supplementation does not improye sprint performance in competitiye swim m ers.
Medicine and Science in Sports and Exercise, 28:1435-1441.
Mujika, I. & Padilla, S. (1997) Creatine supplementation as an ereogenic aid for 
sports performance in highly trained athletes: A critical review. International Journal o f  
Sports Medicine, 18:491-496.
Ôôpik, V., Pââsukem, M., Timpmann, S., Medijainen, L., Erelin, J. & Smimoya, 
T. (1998) Effect o f creatine supplementation during rapid body mass reduction on
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
91
metabolism and isokinetic muscle performance capacity. Eurpoean Journal o f Applied 
Physiology, 78:83-92.
Perry, S.V. (1954) Biochemistry Journal, 57: 427-434.
Plisk, S.S. & Kreider, R.B. (1999) Creatine Controyersy? Strength and 
Conditioning Journal, 21(1): 14-23.
Poortmans, J.R., Auquier, H. & Renaut, V. (1997) Effect of short-term creatine 
supplementation on renal responses in men. European Journal o f Applied Phsiology, 76: 
566-567.
Redondo, D R., Dowling, E.A., Graham, B.L., Almada, A.L. & Williams, M.H. 
(1996) The effect o f  oral creatine monohvdrate supplementation on running yelocity. 
International Journal o f  Sport Nutrition, 6: 213-221.
Rossiter, H.B., Cannell, E.R. & Jakeman, P.M. (1996) The effect o f oral creatine 
supplementation on the 1000-m performance o f competitiye rowers. Journal o f Sports 
Sciences, 14:175-179.
Sahlin, K., Tonkonogi, M. & Soderlund, K. (1998) Energy supply and muscle 
fatigue in humans. Acta Physiol Scand, 162:261-266.
Sapila, I., R^wla, J., SimeU, O. & Vamas, A. (1981) Supplementary creatine as a 
treatment for gyrate atrophy o f the choroid and retina- New England Journal o f 
Medicine, 304: 867-870.
Smith, J.C., Stephens, D.P., Hall, E.L., Jackson, A.W. & Earnest, C.P. (1998) 
Effect of oral creatine ingestion on parameters o f  the work rate-time relationship and time 
to exhaustion in higb-intensity cycling, European Journal o f Applied Physiology, 77: 
360-365.
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
92
Stroud, M.A., Holliman, D., Bell, D., Green, A.L., Macdonald, LA. & Greenhaff, 
P L . (1994) Effect o f  oral creatine supplementation on respiratory gas exchange and 
blood lactate accumulation during steadv-state incremental treadmill exercise and 
recoyery in man. Clinical Science, 87:707-710.
Terrillion, K.A., Kolkhorst, F.W., Dolgener, F.A. & Joslyn, S.J. (1997) The 
effect o f creatine supplementation on two 700-m maximal running bouts. International 
Journal o f  Sport Nutrition, 7: 138-143.
Tesch, P.A., Thorsson, A. & Fujitsuka, N. (1989) Creatine phosphate in fiber 
types o f skeletal muscle before and after exhaustiye exercise. Journal of Applied 
Physiology, 66:1756-1759.
Timson, B.F. (1990) Eyaluation o f animal models for the study of exercise- 
induced muscle enlargement. Journal o f Applied Physiology, 69:1935-1945.
Vandenberghe, K-, Gillis, N., Van Leemputte, M., Van Hecke, P., Vanstapei, F. & 
Hespel, P. (1996) Caffeine counteracts the ergogenic action o f muscle creatine loading. 
Journal o f Applied Physiology, 80:452-457.
Vandenberghe, K., Van Hecke, P., Van Leemputte, M., Vanstapei, F. & Hespel,
P. (1999) Phosphocreatine resynthesis is not affected bv creatine loading. Medicine and 
Science in Sports and Exercise, 31: 236-242.
Westerblad, H., Lee, J.A., Lannergren, J. & Allen, D.G. (1991) Cellular 
mechanisms o f fatigue in skeletal muscle. American Journal o f  Physiology, 261 :C 195- 
C209.
Young, J.C. & Balon, T.W. (1997) Role o f dfliydropyridine sensitive calcium 
channels in glucose transport in skeletal muscle. Life Sciences, 61:335-342.
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
93
Young, J.C., Kandarian, S.C. & Kurowski, T.G. (1992) Skeletal muscle glucose 
uptake following overload-induced hypertrophy. Life Sciences, 50:1319-1325.
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
VTTA
Kinesiology 
University o f Nevada, Las Vegas
Robert Earl Young
Home Address:
1924 Magnolia Dr 
Henderson, NV 89014
Degrees:
Bachelor o f Science, Kinesiology, 1997 
University o f Nevada, Las Vegas
Thesis Title: The Effect o f Dietary Creatine Supplementation on Compensatory Muscle 
Hypertrophy and Performance Characteristics o f Specific Fiber Types.
Thesis Examination Committee:
Chairperson, Dr. Lawrence A. Golding, Ph. D.
Committee Member, Dr. Richard Tandy, Ph. D.
Committee Member, Dr. Carl Reiber, Ph. D.
Committee Member, Dr. Susan Meacham, Ph. D.
Graduate Faculty Representative, Dr. Bryan Spangelo, Ph. D.
94
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
